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HRV AND THE TREATMENT OF MIGRAINES  1 
Abstract 
This dissertation assessed the role of heart rate variability (HRV) in the treatment of migraine 
headaches. The extent of this relationship was measured through a 12-session HRV biofeedback 
protocol to increase HRV and decrease migraine frequency through resonance frequency 
breathing (RFB) training. This project used a single-case design methodology to analyze phase 
changes in physiological variables with a specific focus on changes in HRV and migraine 
symptoms from baseline to completion of the biofeedback protocol. The prevalence of migraine 
headaches is discussed, the history of biofeedback as an intervention for migraine is reviewed, 
and the rationale for the relationship between HRV and somatic symptoms is presented. 
Conceptual frameworks for biofeedback provide rationale for the intervention. The study reviews 
the participant’s history of migraine symptoms, phase changes throughout the protocol, and 
changes in migraine symptoms during the follow-up phase. Overall, the study did not find a 
strong relationship between HRV and migraine symptoms. The participant’s migraine frequency 
decreased throughout the protocol without a significant phase change in HRV. There were 
observed phase changes in other physiological variables consistent with increased autonomic 
regulation. Overall, the HRV biofeedback protocol did have a positive impact on migraine 
symptoms without a significant phase change in HRV. 
Keywords: HRV, biofeedback, migraine, resonance frequency breathing,  









The Role of Heart Rate Variability in the Treatment of Migraines 
Chapter 1 
Statement of the Problem 
Migraines are the most common type of vascular headache, affecting 28 million 
Americans, and cause marked impairment in functioning and quality of life (Sheftell, Cady, 
Borchert, Spalding, & Hart, 2005).  Migraine headaches are estimated to affect 18% of women 
and 7% of men in North America (Pandey, Pandey, & Kumar, 2010). Migraine affects 10-28% 
of children and adolescents, making it one of the most chronic conditions in pediatric 
populations (Verotti et al., 2012). The prevalence of migraine headaches among both adults and 
adolescent populations reflects a burdensome and debilitating condition that affects productivity 
and wellbeing (D’Amico et al., 2011). Migraine headaches result in estimated annual costs 
totaling $13 billion to $17 billion in the United States. This estimated figure includes clinical 
care, medications, emergency room visits, hospitalizations, and management of side effects 
(Goldberg, 2005). The World Health Organization reported migraines as one of the world’s most 
disabling illnesses, which speaks to the need for effective and sustainable treatments (Pandey et 
al., 2010). 
In addition to being an overall health concern, migraines comprise 4.5% of reported 
neuropsychiatric conditions, increasing to 7.1% among women of working age (Leonardi, Raggi, 
Ajovalasit, Bussone, & D’Amico, 2010). The burdensome effects of a migraine headache is not a 
matter of mortality or morbidity, but what constraints and limitations it has on overall 
functioning (Leonardi et al., 2010). Symptoms encountered by migraine sufferers include 
reduced energy, deregulated mood, pain, and occupational impairment (Raggi et al., 2012). 
Migraine sufferers reported that work productivity for both paid work and household chores was 




reduced, averaging between 2.7 and 8.9 days of lost work per year (Prasad, Wahlqvist, Shikiar, 
& Shih, 2004). These lost work days both in and out of the home carry negative implications for 
individuals, families, and the workforce. A critical barrier to successfully treating migraines is 
the misperception that migraine headaches are not a treatable public health problem. This 
societal misunderstanding leads to underdiagnosis, undertreatment, and continued impairment 
(Bigal, Krymchantowski, & Lipton, 2009). 
Migraine 
 Migraines usually begin in adolescence and continue throughout adulthood. Individuals 
experience the greatest prevalence of migraine headaches between the ages of 20 and 45, with an 
average of two episodes per month (Schwedt, Gladstone, Purdy, & Dodick, 2010). Broad 
symptoms can include unilateral throbbing pain, nausea, vomiting, phonophobia, photophobia, 
and aura (Canboim-Rockett et al., 2012). Two common presentations of migraine include 
migraine with aura and migraine without aura and frequency of attacks is differentiated between 
episodic and chronic forms of migraine (Headache Classification Subcommittee of the 
International Headache Society, 2003; Schwedt et al., 2010).    
 Etiology. A migraine is initiated through altered neuronal functioning of the brainstem 
nuclei. More specifically, a migraine can be classified as a subcortical disorder of a specific 
brainstem area. Specific brainstem nuclei, including the periaqueductal grey, nucleus raphe 
magnus, and the locus coeruleus, act as migraine attack generators. These areas continue to be 
activated even after successful implementation of medication, leading researchers to question the 
sustainability of current migraine medications (i.e., triptans). Brainstem activation is specific to 
migraines because it is not observed in primary headache (e.g., cluster headaches, short-lasting 
unilateral headaches) or secondary headache disorders (e.g., the result of another medical 




condition; e.g., Tajti et al., 2012). The activation of specific brainstem regions reflects a unique 
etiology that differentiates migraine from other types of headaches. 
 Triggers. A variety of factors can trigger a migraine headache depending on the 
individual. Some general triggers include changes in sleep routine, delayed or skipped meals, 
changes in stress level, changes in barometric pressure, certain foods, changes in hormone levels 
(i.e., menstruation and ovulation), and caffeine withdrawal (Schwedt et al., 2010). The effect of 
diet on migraine symptoms is a debated topic. Certain food and diet triggers are subjective 
reports by patients and are not uniformly represented in research. However, some foods 
correlating with migraines include chocolate, cheeses, citrus fruits, alcohol, aspartame, 
monosodium glutamate, higher fat foods, dairy products, and caffeine. Additional factors, 
including fasting and insufficient intake of water, also correlate with migraine triggers 
(Camboim et al., 2012). Although dietary factors are not consistent triggers of migraines, they 
remain important areas of exploration in migraine assessment.  
 Stress is important in initiating and maintaining migraine symptoms and will be further 
reviewed in the context of autonomic arousal (Nash, 2011). Camboim et al. (2012) found stress 
to be the most prevalent trigger for migraine headaches, as it was a factor most commonly 
reported by migraine sufferers. An individual’s reaction to stress and physiological changes 
during stress recovery are potential triggers for a migraine (Schwedt et al., 2010). Therefore, 
stress and diet do appear to be triggers for migraines, with stress being the most reliable and 
prevalent indicator. 
Gaps in Current Treatment 
  Current medications used to treat migraines, if used excessively, can induce migraine 
symptoms, which call into question their efficacy in decreasing symptoms and increasing 




vitality. Triptans are a popular type of drug used to treat acute symptoms of chronic migraines. 
They are variable in their effectiveness, with a success rate between 10 and 30%  (Tfelt-Hansen 
& Olesen, 2012). In this study, success was determined by comparing scores from a four-point 
migraine pain scale before triptan treatment and two hours following treatment. Tfelt-Hansen 
and Olsen identified a success when migraine pain decreased a 2 or 3 to a 1 or 0. Triptans are 
coronary constrictors and chronic use can have negative cardiac effects. Overuse has been shown 
to cause serotonergic syndrome, glaucoma, and kidney stones (Bigal et al., 2009). Bigal et al. 
studied migraine symptoms in Denmark and found that the advent of migraine medications, 
namely triptans, had no effect on decreasing work absenteeism. These findings lead Bigal et al. 
to question the efficacy of these drugs in treating symptoms, and to assert the need for an 
alternative, prophylactic treatment to reduce the prevalence of migraines. Although triptans are 
effective for some patients, the variability of their efficacy calls for a more sustainable form of 
treatment. 
 Bigal et al. (2009) found that a significant barrier to migraine treatment is communicating 
the pain to others. Migraines are often presented in primary care settings where symptoms are 
assessed and diagnosed. The brief visit time within a primary care center leaves little time for 
evaluation, diagnosis, and responsive treatment planning (Bigal et al., 2009). Missing or 
incorrectly reported symptoms can lead to an inaccurate diagnosis, which can withhold treatment 
from a suffering individual (Sheftell et al., 2005). Both pharmacological treatment and 
assessment of migraine pose barriers to responsive and effective care. These gaps in current 
treatment encourage health care providers to consider other evidence-supported interventions to 
treat migraine headaches. 
 




Understanding Migraine Symptoms Through Biofeedback 
 Biofeedback is a behavioral tool that uses equipment aimed to “accurately measure, 
process, and feed back to persons and their therapists, information with educational and 
reinforcement properties about their neuromuscular and autonomic activity, both normal and 
abnormal, in the form of analog or binary, auditory, and/or visual feedback signals” (Schwartz & 
Schwartz, 2003, p. 35). Information is gathered and observed through the use of biofeedback 
software that measures levels of physiological and muscular activity. Biofeedback is currently 
used to treat tension-type headaches and migraines with and without aura, as it attends to the 
physiological components in migraine symptomology (Schwartz & Andrasik, 2003). The overall 
goal of biofeedback is to help an individual develop a greater awareness and control of their 
physiological processes that are otherwise outside their awareness (Schwartz & Schwartz, 2003). 
Heart Rate Variability 
 Heart rate variability (HRV) is the variation in the time interval between heart rate beats, 
specifically measuring the rhythmic accelerations and decelerations of the heart. The greater the 
range of these accelerations and decelerations of the heart rate, the greater is the individual’s 
ability to self-regulate, indicating greater flexibility and resiliency of the autonomic nervous 
system. Resilience and self-regulation are at the heart of HRV research as they reflect overall 
coronary health. An important component of HRV is the amplitude and complexity of heart rate 
oscillations. Coronary health is evidenced by a greater amplitude and complexity of heart 
oscillations as it reflects high levels of flexibility and resiliency. This flexibility allows the body 
to self-regulate and restore equilibrium in a more responsive and adaptive manner. Decreased 
HRV makes it difficult for the body to responsively restore equilibrium and recover from 
environmental or physiological changes (Khazan, 2013). Therefore, increasing variation in the 




time interval between heart beats allows for greater coronary flexibility and an enhanced ability 
to self-regulate. 
 Working towards increasing HRV can improve symptoms of coronary disease, artery 
disease, fibromyalgia, irritable bowel syndrome, hypertension, depression, and anxiety. 
Increasing HRV trains the heart to increase its range of activity and allow for more responsive 
adaptations to physiological and environmental changes. Low HRV has been associated with a 
greater mortality rate in patients with heart disease, and increased risk of hypertension, 
depression, and fibromyalgia (Khazan, 2013). Increasing HRV not only positively affects 
coronary health; HRV also has a profound impact on other self-regulatory systems in the human 
body. 
 The primary mechanism for increasing HRV is finding an individual’s resonance 
frequency breathing (RFB) pattern. Khazan (2013) explained that breathing at a particular 
frequency, which differs between individuals, provides the stimulation necessary to maximize 
HRV. For the majority of people, resonance frequency rate falls between 4.5 and 7 breaths per 
minute (bpm). The goal of RF breathing training is to increase the amplitude of heart oscillations 
and the heart’s flexibility (Khazan, 2013). Research indicates that daily practice of resonance 
frequency breathing increases HRV, increases baroreflex, and decreases blood pressure (Lehrer, 
Smetankin, & Potapova, 2000). Biofeedback allows an individual to learn his or her RFB pattern 
and observe how continuing to breathe at that rate increases autonomic flexibility and the body’s 
ability to maintain equilibrium. 
HRV and Migraine Symptoms  
 HRV is a reflection of the interaction between the sympathetic and parasympathetic 
divisions of the autonomic nervous system. The interaction of these systems creates the rhythmic 




fluctuation of an individual’s heart rate during breathing. The sympathetic nervous system 
increases heart rate and is activated during inhalation, whereas the parasympathetic nervous 
system decreases heart rate and is activated during exhalation. Baroreceptors and baroreflex are 
important components in HRV and autonomic activity. Baroreceptors are stretch receptors in the 
blood vessels that detect a rise in blood pressure and signal the heart to slow down. Conversely, 
these baroreceptors send signals to the brain to increase heart rate when blood pressure 
decreases. The negative feedback loop of the baroreceptors, or baroreflex, works to maintain 
homeostasis and systemic health (Khazan, 2013). The activity of the autonomic nervous system, 
namely the baroreceptors, impact HRV and affect the initiation of a migraine and its symptoms. 
 Pandey et al. (2010) posited that cortical hyperexcitability might lead to a reduced 
threshold for experiencing migraine symptoms when in the presence of other triggers. 
Psychosocial stressors can create ischemias, which restrict blood flow and can cause migraine 
symptoms or exacerbate existing distress (Schwartz & Andrasik, 2003). Cortical 
hyperexcitability and restricted blood flow reflect low HRV and difficulty in maintaining 
homeostasis. Autonomic disequilibrium therefore increases the risk of a migraine episode and 
creates the physiological conditions for migraine symptoms. The connection between stress, 
HRV, and migraine symptoms encourages researchers to explore interventions that can help 
individuals respond to stress and increase HRV. A goal of HRV biofeedback is to help the 
individual build awareness around his or her arousal states during stressors and learn techniques 
that help the body return to equilibrium.  
Biofeedback measures that address HRV use regulatory strategies to decrease 
dysfunctional breathing and help patients reach optimal levels of HRV in order to increase 
autonomic flexibility (Courtney, Cohen, & van Dixhoorn, 2011). Therefore, an important area of 




research is studying the relationship between HRV and migraine symptoms and determining 
whether their relationship supports HRV biofeedback as a viable treatment options for migraine 
headaches. 
Summary 
 The salient problems of migraine headaches include: (a) negative impact on overall 
functioning, (b) prevalence across adult and adolescent populations, and (c) variable efficacy and 
potential hazards of current pharmacological treatment. These problems outline the need for 
further research into other variables that affect migraine symptoms and treatment. The 
prospective study will involve an HRV biofeedback protocol designed to decrease autonomic 
dysregulation and strengthen RFB. This study seeks to support the thesis that increased HRV is 

















Chapter 2: Review of Literature 
History of Migraine 
 Migraine research began in the early 1900s and continues today. Tfelt-Hansen and 
Koehler (2011) reviewed one hundred years of migraine research and highlighted the most 
salient findings concerning migraine symptoms, physiology, and treatment. In 1868, ergotamine 
became the first treatment recommendation for migraine symptoms. Sir Henry Dale found that 
ergotamine in liquid form affected the stimulation of sympathetic nerves. This finding lead 
researchers and clinicians to better understand the role of the autonomic nervous system in 
migraine. In 1938, researchers discovered that migraineurs’ cranial arterial walls stretch during a 
migraine attack. Ergotamine treatment was found to specifically narrow and constrict dilated 
arterial walls, decreasing pain symptoms. Research continued to explore the neurological 
components of migraine, including sources of pain and excitatory activity. In 1940, Ray and 
Wolff hypothesized that migraine pain results from the activation of specific structures in the 
brain. Stimulating areas of the brain including the cerebral arteries and the base of the brain 
elucidated the specific regions activated during migraine (Tfelt-Hansen & Koehler, 2011). 
Migraine research at this point created a base for further exploring neural functioning in relation 
to migraine symptoms. 
 In 1941, visual auras were first documented and studied as a component of migraine 
symptomology. Karl Lashley, after documenting his personal experiences with visual auras, 
described the phenomenon as a scotoma, or partial alterations in the visual field that disrupts 
visual acuity, that maintains its shape as it drifts across the visual field. This was the first time 
that these symptoms were explored in relation to migraine headaches. In 1959, researchers began 
to experiment with other types of treatment to decrease the distressing effects of migraine. 




Serotonin was found to be a vasoconstrictor and decrease vasodilation in cranial arteries during 
an acute migraine attack. Synthetic forms of the neurotransmitter were created and had positive, 
albeit variable effectiveness on migraine symptoms. Despite the questionable efficacy of early 
serotonin treatment, utilization of serotonin-based medications did decrease symptoms for 30-
40% of migraineurs (Tfelt-Hansen & Koehler, 2011). Years later, in 1984, researchers began to 
look closer at the relationship between cranial vasodilation and migraine symptoms. At this time, 
the inflammation theory of migraine was proposed based on the abnormal release of substance P, 
a neuropeptide found in the trigeminal nerve of the brain. Although much is still unknown about 
this neuropeptide, its relationship to migraine attacks further buttressed the neurological base of 
this disorder (Tfelt-Hansen & Koehler, 2011). Research between 1941 and the late 1980s 
produced both questions and answers to create the platform for future research. 
 In 1988 came the classification of migraine without aura, which defined a migraine in a 
way that made diagnosis and assessment more extensive and reliable. This diagnosis highlighted 
that aura is not a necessary component in all migraine presentations (Tfelt-Hansen & Koehler, 
2011). The advent of this diagnostic category further clarified the difference between migraine 
and chronic tension-type headaches (Manzoni & Torelli, 2009). During the same year, a new 
serotonin-based treatment was created to treat acute migraine attacks. Sumatriptan, a type of 
triptan, was the first medication created to treat acute migraine attacks and is heralded as a 
landmark discovery in migraine treatment. Its agonist effects on serotonin helped decrease 
vasodilation during attacks, but was still variable in its effectiveness in clinical trials  
(Tfelt-Hansen & Koehler, 2011). Refined diagnostic classification and pharmacotherapy 
enhanced the overall assessment and treatment of migraine. 




 In 1995, positron emission tomography (PET) studies revealed strong brain stem 
activation both during and after a migraine attack. The brainstem was labeled the migraine 
generator, showing activity even after the administration of a triptan medication. PET scans 
showed increased blood flow in the limbic region and the auditory and visual cortices. This 
activity supported the neurologic pathway of the migraine and helped researchers better 
understand why available medications were often variable in effectiveness (Tfelt-Hansen & 
Koehler, 2011). Understanding the role of strong brainstem activation in migraine encouraged 
researchers to explore the heritability of this neurologic disorder. 
 The genetic underpinnings of migraine became a focus of research in 1996. Migraineurs 
with and without aura were studied in the hopes of elucidating the heritability to migraine.  
First-degree relatives of migraineurs without aura had 1.9 times the risk of having migraine 
without aura and 1.4 times to risk of having migraine with aura compared to the general 
population. This research also found that first-degree relatives of migraineurs with aura had 4 
times the risk of having the disorder and no increased risk for migraine without aura  
(Tfelt-Hansen & Koehler, 2011). These findings suggest that migraine has notable genetic 
underpinnings, especially migraine without aura. 
 In 2004, the term chronic migraine first officially appeared in the International 
Classification of Headache Disorders (2nd ed.). This label supplanted the term transformed 
migraine and created a diagnostic category for migraine symptoms that extend beyond episodic 
criteria (Manzoni & Torelli, 2009). This shift in nomenclature confirmed the chronic 
presentation of migraine as a distinct diagnostic entity that occurs in greater frequency than 
episodic migraines. Episodic migraine can transform into chronic migraine and with this shift 
comes a more specific classification. Current migraine research continues to focus on migraine 




symptomology, physiology, and treatment, using previous research to guide new avenues of 
study. 
Sex Differences 
 Migraine affects men and women in different ways that are necessary to review and 
understand for the purposes of the proposed research. Migraine occurs twice as often in females 
than males (Maleki et al., 2012a). Males are less frequently studied than females in migraine 
research, which affects their representation in the literature. Maleki et al. (2012a) posited that the 
female brain often evidences greater levels of dysfunction in the networks of the brain activated 
during migraine. This dysfunction leads to increased autonomic deregulation, which can be 
exacerbated by the menstrual cycle. Female migraineurs typically experience their first attack 
soon after menarche, with a brief reprieve during pregnancy and cessation after menopause. Both 
an increase and decrease of estrogen is closely correlated with migraine symptoms. Sacco, Ricci, 
Degan, and Carolei (2012) reported that estrogen increases cortical hyperexcitability and 
increases migraines with aura. These findings suggest that estrogen levels play a crucial role in 
migraine symptoms and the schedule of attacks. Therefore, hormonal excretion, namely 
estrogen, appears to be a reliable variable that accounts for the differences in migraine frequency 
between men and women. 
 Pain experiences. Although pain thresholds are similar between the sexes, females report 
higher levels of discomfort during a migraine attack. Maleki et al. (2012a) found that male and 
female migraineurs differ in what structures are affected during a migraine attack. In their 
research, females were found to have more pronounced responses in their amygdala and 
parahippocampal gyrus. Activation of these areas is associated with stress, anxiety, and increased 
perceptions of pain. Males have lower activation of these regions, providing an explanation for 




their lower ratings of reported pain during a migraine. Therefore, activation of specific brain 
structures accounts for some of the differences in pain perception between male and female 
migraineurs. 
Varieties of Migraine 
 The varieties of migraine reviewed in this study include: (a) migraine with aura, (b) 
migraine without aura, (c) episodic migraine, and (d) chronic migraine. Migraines with aura and 
without aura are types of headache with specific diagnostic criteria and clinical presentations. 
Both episodic and chronic labels are not used for diagnostic purposes, but rather to specify the 
frequency and duration of migraine experienced by participants. Episodic and chronic diagnoses 
are distinct entities and are not used to inform the assessment or treatment phases of the study. 
Rather, they are outlined to inform the researchers about the varying frequencies that migraine 
headache can occupy. The HRV biofeedback protocol seeks to study individuals that suffer from 
migraine without aura due to its prevalence and impact its symptoms have on overall functioning 
and quality of life. Migraine with aura is reviewed to inform the research of additional 
neurological symptoms that can accompany migraine symptoms. The following diagnostic 
review of migraine without aura and migraine with aura is provided by the International 
Classification of Headache Disorders (2nd ed.; Headache Classification Subcommittee of the 
International Headache Society [ICHD-II], 2003). 
 Migraine with aura. The diagnostic criteria for migraine with aura include at least two 
headache attacks lasting 4-72 hours where diagnostic criteria for aura are met. Aura symptoms 
must include at least one of the following symptoms without motor weakness: (a) fully reversible 
visual symptoms including positive features (e.g., flickering lights, spots or lines) and/or 
negative features (i.e., loss of vision), (b) fully reversible sensory symptoms including positive 




features (i.e., pins and needles) and/or negative features (i.e., numbness), and (c) fully reversible 
dysphasic speech disturbance. Aura symptoms must also include least two of the following: (a) 
homonymous visual symptoms and/or unilateral visual symptoms, (b) at least one aura symptom 
develops gradually over >5 minutes and/or different aura symptoms occur in succession over >5 
minutes, and (c) each symptom lasts >5 and <60 minutes. Headache fulfilling the criteria for 
migraine without aura begins during or follows the aura within 60 minutes and is not attributed 
to another disorder. The headache must include two of the following symptoms: (a) unilateral 
location, (b) pulsating quality, (c) moderate or severe pain intensity, and (d) aggravation by or 
causing avoidance of routine physical activity. During the headache at least one of the following 
symptoms are experienced: (a) nausea and/or vomiting and (b) photophobia and/or phonophobia. 
Diagnostic criteria for migraine with aura are only fulfilled if both the headache and aura 
symptoms are not attributed to another disorder (Headache Classification Subcommittee of the 
International Headache Society, 2003). Aura occurs in 20% of episodic migraines and last 
between 5 and 60 minutes. The common most type is visual aura, experienced as flickering 
lights, spots, and/or visual blurriness (Schwedt et al., 2010). 
 Migraine without aura. The diagnostic criteria for migraine without aura include at 
least five attacks with each attack lasting 4-72 hours. The headache must have at least two of the 
following characteristics: (a) unilateral location, (b) pulsating quality, (c) moderate or severe 
pain intensity, (d) and aggravation by or causing avoidance of routine physical activity. During 
the headache at least one of the following symptoms are experienced: (a) nausea and/or vomiting 
and (b) photophobia or phonophobia. These symptoms cannot be attributed to another disorder in 
order to fulfill diagnostic criteria (Headache Classification Subcommittee of the International 
Headache Society, 2003). 




 Episodic migraine. Episodic migraine without aura is diagnosed when at least five 
attacks in one month fulfill the following criteria: episodes lasting between 4 and 72 hours and 
nausea/vomiting or photophobia/phonophobia. At least two of the following must be present 
during these five attacks: (a) unilateral location, (b) pulsating sensation, (c) moderate to severe 
pain, and (d) aggravation by of causing avoidance of routine physical activity. Associated 
symptoms can include dizziness, lethargy, change in mood, difficulty concentrating, and aura 
(Schwedt et al., 2010).  
 Differential diagnosis. The differential diagnosis between episodic and chronic migraine 
headaches can be difficult due to their similar symptomology. Both Katsarava et al. (2010) and 
Camboim-Rockett et al. (2012) reported that migraines become chronic when diagnostic 
symptoms are met more than 15 days per month. Therefore, episodic migraine is the term used 
when symptoms are experienced 15 or fewer days per month. Despite this demarcation in 
diagnosis there is a risk of episodic migraines becoming chronic. Researchers found that episodic 
migraineurs (3% in the general population and 14% in a clinic-based sample) can transform into 
chronic migraineurs depending on their level of risk and medical history. The risk factors to 
chronic transformation include being female, low socioeconomic status, young age within the 
migraine spectrum, and a history of head or neck injuries. Other, more modifiable risk factors 
include obesity, overuse of migraine medication, stress, sleep disturbances, depression, and high 
caffeine intake (Schwedt et al., 2010). The differential diagnosis between episodic and chronic 
migraine is difficult due to the prevalence of transformed migraines. However, this research will 
utilize the operational definitions outlined by Katsarava et al. and Camboim-Rockett et al. to 
determine the specific type of migraine. 
 Chronic migraine. A chronic migraine is diagnosed if an individual experiences 




headache 15 or more days per month for three or more consecutive months. Migraine symptoms 
must be present on at least 8 of the 15 headache days during the month. Again, like episodic 
migraines, chronic migraines may present with or without aura. Chronic migraines, including 
migraines that transformed from episodic to chronic, affect 2-3% of the general population.  
Aside from the prevalence rate of 15 or more days per month, the symptomology of a chronic 
migraine is identical to an episodic migraine (Headache Classification Subcommittee of the 
International Headache Society, 2003; Schwedt et al., 2010). However, chronic migraineurs 
experience a greater degree of impairment in cortical processing of sensory stimuli due to 
consistent cortical hyperexcitability (Katsarava et al., 2010). The chronic presentation of head 
pain increases the risk of including other types of headaches diagnoses (i.e., chronic tension-type 
headache). Therefore, medical professionals need to closely adhere to the aforementioned criteria 
to ensure a correct diagnosis (Manzoni et al., 2011).  
Stages of Migraine 
 There are four main stages of migraine headache: (a) prodrome, (b) aura, (c) head pain, 
and (d) postdrome. First, the prodrome stage can last up to 24 hours prior to the full onset of a 
migraine and include affective and vegetative symptoms. The aura stage typically lasts up to one 
hour, but as previously mentioned does not affect all migraine sufferers. Head pain is often the 
most debilitating stage, lasting up to 72 hours and negatively affecting functioning. Lastly, the 
postdrome stage is evidenced by extreme fatigue and mildly depressed mood that follows the 
experience of head pain (Khazan, 2013). These four stages occur in most migraine headaches 
and are important markers for their differences in symptoms and pain experience.  
History of Biofeedback and Migraine 
 The research and utilization of applied biofeedback began in the late 1950s and continues 




today. Biofeedback became a focus when clinicians began to understand the responsiveness of 
the autonomic nervous system to principles of operant conditioning. Biofeedback research and 
training with humans and animals showed that bodily responses could be mediated through 
behavioral changes. Important physiological components in this research involved vasomotor 
responses, galvanic skin response (GSR), blood pressure, and cardiac activity. Research at that 
time suggested that increased awareness of their physiological processes could lead to behaviors 
that strengthen control over some autonomic functions (Grazzi, 2007). These findings created the 
structure for research that would focus on the relationship between autonomic processes and 
health-related conditions. 
 Biofeedback research in the 1970s further highlighted the relationship between 
autonomic arousal and chronic psychophysiological tension. Therefore, the goal of applied 
biofeedback became decreasing overall autonomic arousal and promoting self-relaxation and 
self-regulatory behaviors. Common indicators of autonomic arousal include muscle tension, 
rapid heart rate, dysregulated respiration, and changes in skin temperature. Researchers found 
that the aforementioned symptoms, which are indicative of sympathetic activation, were related 
to the physiological symptoms of migraineurs. This led to a rapid expansion of biofeedback 
literature during the 1970s and 1980s that reviewed the relationship between migraine symptoms 
and autonomic dysregulation (Grazzi, 2007). The hope was that biofeedback treatment could be 
expanded throughout different health disciplines to foster cost-effective, non-invasive treatment 
to a wide range of individuals. 
 Biofeedback for migraine is conceptualized through the physiological dysregulation 
model. This model suggests that individuals are often unable to attend to their physiological state 
and are therefore unaware of how to maintain autonomic control and avoid dysregulation 




(Schwartz & Andrasik, 2003). Research indicates that migraines are exacerbated by an 
individual’s difficulty in recovering from stress (; Maleki, Becerra, & Borsook, 2012b; Turk, 
Meichenbaum, & Genest, 1983). More specifically, these individuals have a maladaptive 
response to stressors rooted in regular episodes of autonomic dysregulation. These authors 
believed that behavioral measures, namely biofeedback, could help enhance an individual’s 
autonomic control and stress recovery. The histories of biofeedback and migraine share roots in 
the assessment and treatment of autonomic dysregulation through learned and practiced 
techniques aimed to restore autonomic regulation. 
 Finger temperature. Thermal biofeedback is an established treatment of migraine 
headache. Biofeedback practitioners focus on hand warming techniques to increase fingertip 
temperature and peripheral vasodilation. This technique is often used in conjunction with 
autogenic training to warm the hands and loosen arterial tension (Blanchard et al., 1997). An 
increase in fingertip temperature is indicative of dilated blood vessels and a decrease in 
sympathetic activity (Grazzi, 2007). The goal of thermal biofeedback is to observe a gradual 
increase in fingertip temperature within and between sessions. A higher fingertip temperature 
reflects relaxation and a decrease in sympathetic activity. Sympathetic activation leads to 
preparation for a stress response and signals the smooth muscles of peripheral blood vessels to 
contract. This muscle contraction constricts blood vessels and lowers skin temperature, which is 
part of the migraine process. Thermal biofeedback and autogenic training decreases sympathetic 
activation, allowing for relaxation of the smooth muscles and dilation of peripheral blood vessels 
(Grazzi, 2007). 
 Research about the efficacy of thermal biofeedback remains mixed. Some critics report a 
scarcity of controlled experiments evidencing the effectiveness of thermal biofeedback, which 




weakens it as an evidence-based option for migraine. Blanchard et al. (1997) found no significant 
difference between thermal biofeedback and control groups. Although participants reported a 
decrease in headache frequency there was no reduction in pain symptoms. Thermal biofeedback 
appears to be variable in its efficacy, which prompts biofeedback practitioners to review other 
areas of research. This research extends to exploring alternate physiological processes related to 
stress, autonomic activity, and migraine. 
Efficacious Applications of HRV Biofeedback 
 Biofeedback practitioners utilize HRV as a measurement because it is a stable marker of 
autonomic adaptability and health. HRV biofeedback focuses on low-paced breathing exercises 
aimed at enhancing relaxation and decreasing autonomic and emotional dysregulation.  
Slow-paced, controlled breathing increases respiratory sinus arrhythmia (RSA), an indicator of 
HRV. RSA reflects the rhythmic accelerations and decelerations of the heart rate in synchrony 
with breathing, meaning that heart rate increases during inhalation and decreases during 
exhalation. This pattern reflects the distinct influences of the parasympathetic (HR decrease 
during exhalation) and sympathetic (HR increase during inhalation) nervous system (Song & 
Lehrer, 2003). HRV proves to be an importance indicator of autonomic functioning that has 
noteworthy implications for a range of behaviors and health issues. 
 Self-regulatory tasks. Reynard, Gevirtz, Berlow, Brown, and Boutelle (2011) studied 
HRV to determine its role during controlled, self-regulatory tasks. Theses authors viewed HRV 
as a measure of self-control capacity due to its relationship with autonomic functioning. 
Furthermore, they posited that self-regulatory behaviors involve restraint, which lower energy 
output and conserve glucose. This process was shown to decrease levels of reported stress and 
increase HRV. Therefore, this supported the hypothesis that self-regulatory efforts (e.g., 




breathing exercises) increase HRV. However, this relationship was inconsistently found 
throughout the literature and warrants further research. Reynard et al. suggested that future 
research be aimed at confidently determining the effects that HRV biofeedback has on  
self-regulatory tasks. This is an area of interest for many health-related issues that contain  
self-regulatory components including obesity, chronic stress, diet, and medication compliance 
(Reynard et al., 2011). 
 Fibromyalgia. Hassett et al. (2007) treated 12 female participants with HRV biofeedback 
to decrease symptoms of pain and depression. The goal of HRV biofeedback is to target 
autonomic reactivity and work towards maximizing the amplitudes of HRV. This is achieved 
through RFB, which strengthens baroreflex and improves autonomic balance. The treatment 
focused on teaching the participants to breath at their resonant frequency breath during scheduled 
times each week to work towards decreasing sympathetic activation. The participants reported an 
overall decrease in both pain and depression symptoms after a 3-month follow-up. The follow-up 
also evidenced an increase in HRV among all participants, evidencing the role that autonomic 
changes plays in fibromyalgia symptoms (Hassett et al., 2007). These findings suggest that HRV 
biofeedback can be a successful treatment to decrease pain and depression symptoms 
experienced by female fibromyalgia patients. 
 Pain disorders. The perception of pain has sensory and affective components that disturb 
homeostasis and the body’s ability to relax and regulate. Biofeedback with pain focuses on the 
relationship between affective states and autonomic arousal, viewing both as learned and 
automatic reactions to the environment. Greater HRV is associated with an increased capacity to 
regulate affect, which is closely linked to how pain is experienced (Appelhans & Luecken, 
2008). HRV is used as an index for emotionality and used to measure pain sensitivity and 




perception during biofeedback training with pain patients. Appelhans and Luecken concluded 
found that pain is likely regulated and influenced by autonomic activity, specifically the body’s 
ability to maintain homeostasis. HRV is an important construct that connects autonomic activity 
and emotion in the experience and perception of pain. 
 Prehypertension. Prehypertension is associated with cardiac risk factors due to high 
blood pressure and decreased baroreflex. Individuals with hypertension have low HRV and an 
increase in sympathetic activity. Decreased HRV is associated with increased cardiac mortality 
and morbidity, which is a major health concern (Lin et al., 2012). Therefore, the goal of HRV 
biofeedback in treating prehypertension is to increase HRV and decrease blood pressure, namely 
through RFB. Breathing at resonance frequency stimulates the baroreceptors and increases HRV 
amplitudes. Breathing retraining will increase low-frequency breathing, increase baroreflex 
sensitivity, and decrease blood pressure. Lin et al. found that HRV biofeedback could enhance 
baroreflex sensitivity and facilitate the adjustment of blood pressure in prehypertensive 
individuals. 
 Heart failure. Swanson et al. (2009) conducted a study applying HRV biofeedback with 
patients recovering from heart failure. The authors has each participant undergo 6 sessions of 
breathing retraining to increase HRV and decrease autonomic dysregulation. Heart failure is 
associated with autonomic imbalance, namely an increase in sympathetic activity. Chronic 
sympathetic activity (hyperarousal) is taxing on the heart and weakens cardiac reflexivity. 
Breathing retraining is therefore a core technique in helping heart failure patients increase their 
cardiac health and resiliency. Breathing retraining increased patients’ tolerance and endurance 
during simple exercise tasks (e.g., walking short distances), which is a strong indicator of cardiac 
health and rehabilitation in health failure patients (Swanson et al., 2009). However, the authors 




did not find a robust change in HRV after 6 sessions of breathing retraining. Rather, the practice 
of breathing retraining appeared to positively impact cardiac health and resiliency without 
requiring a significant increase in HRV. Breathing retraining and HRV biofeedback, even 
through a brief treatment protocol, can positively affect overall cardiac functioning in this 
vulnerable population without a marked increase in HRV. These findings are important for the 
current study as HRV is hypothesized to increase through resonance frequency biofeedback 
training. 
 Cognitive stress. Chronic stress negatively affects cognitive functioning and increases 
error making. Sympathetic activation impairs working memory, likely due to increased cortisol 
concentration in the blood. Increased HRV is correlated with faster reaction time and a higher 
frequency of correct responses to cognitive tasks. Prinsloo et al. (2011) measured participants’ 
baseline HRV and gave them RFB training. Then, participants were given a hand-held HRV 
device that measured that measured their breathing pattern and HRV. Prinsloo et al. found that 
increased HRV improved relaxation, cognitive performance, and was effective in enhancing 
relaxation and concentration. The study ultimately concluded that short duration HRV 
biofeedback is associated with improved performance on cognitive tasks and improved levels of 
reported relaxation during the tasks (Prinsloo et al., 2011). 
Summary 
 Over 100 years of research has produced important findings about migraine etiology, 
physiology, assessment, and treatment. Migraine can be either episodic or chronic in presentation 
and affect men and women in different ways. The discrepancy in prevalence and pain symptoms 
between the sexes is a noteworthy finding that is important in migraine assessment and 
treatment. Applied biofeedback with migraine is a longstanding intervention that works towards 




decreasing physiological dysregulation and increasing self-regulatory capacities and behaviors. 
Fingertip temperature, namely hand warming, was an established behavioral treatment for 
migraine. However, its variable efficacy encourages biofeedback practitioners to explore other 
types of physiological constructs. HRV biofeedback emerged as an efficacious treatment for a 
range of behaviors and health issues including self-regulation, fibromyalgia, pain disorders, 
prehypertension, cardiac failure rehabilitation, and cognitive stress. 
Purpose of the Study 
 The purpose of the study was to determine if there is a relationship between HRV and 
migraine without aura symptoms. There is early evidence that an individual’s headache 
symptoms decrease as HRV increases (Khazan, 2013). This research sought to better understand 
how changes in HRV affected reported migraine without aura symptoms. The biofeedback 
instrument measured HRV in addition to heart rate, respiration, and skin conductance. 
Biofeedback was not the treatment or intervention, rather it was a method of measuring and 
observing physiological activity in the body. Biofeedback equipment was the primary device 
used to measure physiologic phase changes and responses during the study. The treatment was 
the specific biofeedback protocol designed to increase HRV through RFB exercises. Overall, the 
goal of this study was to determine if an increase in HRV is correlated with a decrease in the 
severity and frequency of reported migraine without aura symptoms. The inverse relationship 
between HRV and migraine symptoms can create an alternative behavioral treatment that avoids 
the negative side effects of current pharmacotherapy.  
Research Hypothesis 
 This study hypothesized that an increase in HRV, facilitated through biofeedback 
training, will potentially decrease the frequency and intensity of migraine symptoms. More 




specifically, individuals that have biofeedback treatment increase their HRV and are therefore 
less likely to experience migraine symptoms. HRV biofeedback allowed the participant to 
observe different physiological signals and understand how stressors affect his autonomic 
nervous system. Another component of the hypothesis is that the participant will be able to use 
behavioral strategies learned during HRV biofeedback training (e.g., RFB skills) to decrease his 






















Chapter 3: Method 
 This study sought to answer the question of whether an increase in HRV led to a decrease 
in migraine symptoms. The biofeedback protocol was comprised of 10, 30-minute sessions that 
focus on RFB determination and training. The research question was addressed using a  
single-case design in which the biofeedback intervention was administered in the context of 
ongoing monitoring of HRV and migraine symptoms. The key component to this research design 
was to associate the introduction of RFB training intervention with (a) changes in HRV and (b) 
reduction of migraine symptoms (Kazdin, 2003).  An AB design was the most appropriate 
framework for this single-case research because it measured the baseline values of HRV and 
reported migraine symptoms (A), applied the HRV biofeedback intervention (B), and measured 
the change over time. This HRV biofeedback intervention was the variable that defines the phase 
change and was hypothesized to increase HRV and decrease migraine symptoms (Kazdin, 2011). 
Participants 
 This single-case design used one participant who reported symptoms of migraine without 
aura. This participant was recruited through a network of health psychologist and primary care 
physicians in the Boston and Greater Boston area. The researcher planned on recruiting 5 
participants and had to adjust the sample size due to problems in the recruitment process. This 
single-case study maintained its methodological and statistical integrity despite this change in 
sample size. A single-case design is supported in both the biofeedback and single-case design 
literature and does not require a minimum number of participants to determine power (Kazdin, 
2011). Song and Lehrer (2003) supported a small sample size (N=5) in their HRV RFB 
biofeedback protocol. The participant’s primary care provider offered the participant reporting 
migraine symptoms within the past month a recruitment letter that outlined the area of research, 




goals for the study, and the next step involved in the screening process (see Appendix A).  
Recruitment and Screening 
 Individuals interested in participating in the study contacted me for a telephone 
screening. I reviewed items on the Migraine Symptom Tool (see Appendix B) to determine if the 
participant met diagnostic criteria for migraine without aura and fulfilled other inclusion criteria. 
Recruitment was conducted between March and September 2014 with only one individual 
meeting full inclusion criteria. The participant and I scheduled an initial orientation meeting. The 
post-screening meeting between the primary investigator and participant had the following 
objectives: (a) review and sign informed consent form (see Appendix C), (b) review and hand 
out two Migraine Logs and two Descriptive Migraine Logs to log baseline data of migraine 
frequency and pattern, and (c) schedule all biofeedback sessions. The participant accepted into 
the study was assigned an alphanumerical code to ensure confidentiality of the data. 
 The following inclusion and exclusion criteria align with the behavioral clinical trials 
guidelines created by a workgroup under the auspices of the American Headache Society 
(Penzien et al., 2005). 
Inclusion Criteria 
 Individuals who received the recruitment letter and contacted me were required to meet 
the following criteria: (a) fulfillment of International Classification of Headache Disorders (2nd 
ed.; Headache Classification Subcommittee of the International Headache Society [ICHD-II], 
2003) diagnostic criteria for migraine without aura, (b) a self-report of 5 or more headache 
attacks within the past month (Migraine Symptom Tool, see Appendix B), (c) a stabile pattern of 
headache episodes for at least one year, (d) a stable pattern of headache symptoms for a period of 
6 months or more, (e) 18 years of age or older, and (f) English-speaking. The study only selected 




English-speaking participants 18 years of age or older to maintain the validity and reliability of 
the biofeedback protocol.   
 As a part of the informed consent process, the recruited participant agreed to participate 
in all 10 biofeedback sessions, fill out daily symptom logs, and partipate in monthy follow-up 
assessment phone calls for a period of 3 months. The study also asked participants to report their 
usual use of headache medication and requested that he do not make any changes to this regimen 
during this study. The participant was asked to inform me if an adjustment in his medication 
regimen is medically indicated and utilized. 
Exclusion Criteria 
 People were excluded from the study if any of the following criteria were met: (a) failure 
to meet any of the inclusion criteria specified above; (b) women who were pregnant, planning 
pregnancy during the study period, or lactating as these variables exert a powerful influence on 
migraine symptomology; (c) if the individual had substantial medical or psychiatric 
comorbidities that would interfere with his or her participation in the study; and (d) any 
participant who declined to attend all 10 sessions of the biofeedback protocol and participate in 
the 3-month follow-up outcome assessment were withdrawn from the study. 
Measures 
Migraine Symptom Tool (MST) 
 The Migraine Symptom Tool (MST) is a screening checklist created by the primary 
researcher of this study to determine if a potential participant’s self-reported headache symptoms 
met diagnostic criteria for migraine without aura and inclusion criteria. The items on this 
symptom tool strictly adhere to the diagnostic criteria for migraine without aura outlined in the 
International Classification of Headache Disorders (2nd ed.; Headache Classification 




Subcommittee of the International Headache Society [ICHD-II], 2003). The MST, in addition to 
diagnostic criteria, determined stability of reported migraine headaches by addressing the 
frequency to headache attacks and associated symptoms.  
Migraine-Specific Quality of Life Questionnaire (MSQ 2.1) 
 The Migraine-Specific Quality of Life Questionnaire (MSQ 2.1) is one of the most 
frequently utilized tools to assess health-related quality of life (Bagley et al., 2012). This 14-item 
instrument was used to measure the impact of migraine headaches on the participant’s quality of 
life during the study. The MSQ 2.1 measures the impact of migraine symptoms over the past four 
weeks within three distinct dimensions: (a) role function restrictive (RR), (b) role function 
preventive (RP), and (c) emotional function (EF; Bagley et al., 2012). The RR dimension has 7 
items that assess how migraines limit daily routine and social functioning; the RP dimension has 
4 items that assess how migraines prevent daily activities; and the EF dimension assesses 
emotions associated with migraine episodes (Rendas-Baum, Bloudek, Maglinte, & Varon, 2013). 
The MSQ 2.1 was validated in a clinical sample of 458 migraine patients and has high internal 
consistency, moderate to strong convergent validity, and reliable discriminant validity (Bagley et 
al., 2012). The participant answered each items according to a 6-point Likert scale and the raw 
total was transferred to a 0-100 point scale. Larger scores indicated a better quality of life and 
helped to describe the subjective impact of migraine for the participant (Bagley et al., 2012; 
Rendas-Baum et al., 2013). 
 The MSQ 2.1 was administered during Sessions 1, 5, and 10 to measure the effect of 
migraine on the participant’s quality of the life. This instrument was administered once per 
month during the 3-month follow-up period. 
 





 Migraine symptoms were measured using both the Migraine Log (see Appendix D) and 
the Descriptive Migraine Log (see Appendix E). These tools are self-report measures that 
allowed the participant to log, describe, and rate his migraine experiences throughout treatment. 
These logs were provided to the participant two weeks prior to the first biofeedback session. The 
participant was asked to fill out these logs for the two weeks prior to the first biofeedback 
session. A two-week baseline is the minimum requirement for assessing the frequency, pattern, 
and symptoms of migraine headache (Headache Classification Subcommittee of the International 
Headache Society, 2003). These migraine logs were used to continuously measure migraine 
symptoms and the changes in level of distress over the course of biofeedback treatment. The 
participant was asked to fill out these daily logs for a total of 3 months following the final 
biofeedback session. The primary investigator called and emailed the participant at the end of 
each month to collect data from the logs to satisfy follow-up assessment criteria (Penzien et al., 
2005). 
Biofeedback Specific Measurements 
 The HRV biofeedback protocol required a computerized instrument that measured 
breathing rate, heart rate, HRV, skin conductance, and finger temperature. The I-330-C2 Plus  
12-channel biofeedback device (J&J Engineering; 2004) supports simultaneous monitoring of 
these signals and is the method of measurement for this protocol. The software displays signals, 
provides visual feedback, continuously collects data, and prints reports (J&J Engineering, 2004). 
This is a supported instrument used throughout the literature in biofeedback and HRV protocols. 
 Breathing rate. The respiration rate of the participant was measured with a lower 
abdomen breathing belt. The breathing belt is worn around the waist and measured the rate of 




breathing, its pattern, and proportion of inhalations and exhalations. The typical breathing rate is 
12 bpm and the proposed HRV biofeedback protocol works to decrease this frequency and 
promote RFB (Khazan, 2013). Breathing was measured throughout each protocol with the goal 
being for the participant to learn to breathe at resonance frequency. 
 Heart rate and HRV. Heart rate and HRV are different variables, but share similar 
methods of measurement on the biofeedback equipment. Three frequencies are used to display 
activity of the heart at each movement and the ranges of heart activity: (a) high frequency, (b) 
low frequency, and (c) very low frequency. High frequency displays the signal range between 
0.15 and 0.4 hz which reflects vagal tone and parasympathetic activity. Low frequency displays 
the signal range between 0.05 and 0.15 hz and reflects baroreflex maintenance. High activity in 
this frequency reflects RFB and is known as the meditator’s peek. Very low frequency displays 
the signal range between 0.005 and 0.05 hz and is primarily influenced by sympathetic activity 
(Khazan, 2013). These three distinct frequencies are integral in measuring HRV throughout the 
RFB protocol. 
 An electrocardiogram (ECG) also measures heart rate and is illustrated by R-waves by 
the biofeedback software. An R-wave represents a contraction of the ventricles and illustrates the 
beating of the heart on the computer screen for both the participant and administrator to observe. 
The R-R interval represents the normal-to-normal interval between heartbeats. The difference in 
R-R intervals is calculated and used to determine HRV (Khazan, 2013). 
 Peak-to-trough is a clinical measurement of HRV and measures the difference between 
the maximum and minimum (max-min) heart rate that occurs during a single breath cycle. The 
peak-to-trough method compares R-R intervals over the many breath cycles during the protocol 
and determines HRV. Typical HRV levels are dependent on age as younger individuals have 




higher HRV than older adults. HRV of 10 beats per minute is considered healthy for most adults. 
The following values are considered healthy peak-to-trough HRV levels; 20 beats per minute for 
children and adolescents, 3-6 beats per minute for adults over 50, and 25-35 beats per minute for 
adult athletes. These values are a guide for determining a healthy peak-to-trough HRV and the 
protocol worked to increase HRV throughout the 10 sessions. 
 Skin conductance. Skin conductance, also referred to as a galvanic skin response, is an 
objective measure of sympathetic nervous system activation (Banks, Bellerose, Douglas, & 
Jones-Gotman, 2012). Biofeedback sensors measure the amount of electricity conducted through 
the skin and reflect the skin’s ability to conduct electrical activity. The amount of skin 
conductance, measured in micromhos or microseimens, is dependent on the amount of moisture 
produced by eccrine sweat glands. Values of skin conductance are subjective, but the following 
ranges are used in biofeedback assessment: 1 micromho is low, between 5 and 10 is high, and 
between 2 and 5 is typical. Higher values reflect sympathetic activation and lower values 
represent relaxation and parasympathetic response (Khazan, 2013). The subjective nature of skin 
conductance required constant observation for phase changes before and after each biofeedback 
session. 
 Finger temperature. Finger temperature is an indicator of sympathetic activation and is 
measured with a small sensor of the tip of the index finger. This is a commonly used variable in 
migraine research (e.g., thermal biofeedback, finger warming techniques) and is important in 
measuring levels of sympathetic activity during treatment. Typical finger temperature readings 
for healthy adults are between 88 and 95 degrees Fahrenheit. The goal was to raise this value 
above 90 degrees. Ideally, a value of 95 degrees Fahrenheit is an excellent indicator of decreased 
sympathetic activity and increased relaxation (Khazan, 2013). Individuals often vary in their 




baseline temperatures. Therefore, the focus was on the relative increase in the participant’s finder 
temperature compared to his baseline. Tracking this phase change is more meaningful than 
strictly comparing it to the ideal of 95 degrees. For the purposes of this research, values of about 
90 degrees were considered satisfactory. 
Data Collection 
RFB Protocol 
 The following is based on Lehrer’s (2007) protocol for RFB training combined with 
additional session details suggested by Khazan (2013). This 10-session HRV biofeedback 
protocol is supported in the literature and is specifically used to increase HRV through RFB. 
Sessions lasted approximately 30 minutes to provide ample time for data collection, discussion 
of the protocol between participant and administrator, and analysis of phase changes. All 
sessions were held at the Boston Center for Health Psychology and Biofeedback, a private 
practice owned and operated by licensed clinical psychologist and board certified biofeedback 
provider, Inna Khazan, Ph.D., BCB.  Biofeedback sessions were held in a private office to 
maintain participant confidentiality. The participant tracked his migraine symptoms through  
self-report and symptom logs 2 weeks prior to the first biofeedback session. 
 Sessions 1-3: Determining resonance frequency breathing. Resonance frequency 
breathing occurs between 4.5 and 7 bpm, with an average resting around 6 bpm. The first two 
sessions were dedicated to breathing training and determining resonance frequency breathing. 
The first step in Session 1 was to teach diaphragmatic breathing skills, focusing on low and slow 
breathing evidenced by a 40% inhalation and 60% exhalation pattern. Next, the researcher 
obtained a baseline of breaths per minute once the participant was comfortable with the 
diaphragmatic breathing practice. The foci of Session 1 were to help determine a baseline of 




breaths per minute and prepare the participant for paced breathing during Session 2. 
 Session 2 began with RFB training with the use of a breathing pacer displayed on the 
computer screen. The first step in paced breathing involved decreasing the participant’s baseline 
breaths per minute by 1-2 points and having the participant follow the pacer at that rate. The 
participant was instructed to breathe at that rate for 2 minutes and make adjustments based on 
adherence to the frequency. The goal of paced breathing at that point was to practice until the 
participant was able to breathe at 7 bpm. This protocol did allow for paced breathing training at  
7 bpm to extend into Session 3 depending on participant performance. 
 Session 3 was focused on determining RFB after the participant was comfortable with 
paced breathing at 7 bpm. First, the pacer was set at 7 bpm and the participant was asked to 
practice low and slow breathing while following the pacer for 3 minutes (1 minute of breathing 
adjustment and 2 minutes of recorded breathing). I observed the participant’s low frequency 
peak, HRV max-min, heart rate, and estimated RSA during the breathing exercise. These values 
and observations were recorded on the Resonance Frequency Breathing Rate Determination 
Table (see Appendix F; Table 1). I set the pacer a half of a point down (6.5 bpm) and allowed 
one minute for breathing adjustment and two minutes of recorded breathing after this three 
minute period. These steps were repeated until the participant follows the pacer at 4.5 bpm. RFB 
was determined after the data on the Resonance Frequency Breathing Rate Determination Table 
is reviewed. We reviewed the session and discussed the results recorded on the aforementioned 
table. The participant’s RFB pattern was determined at the conclusion of this session. 
 Sessions 4-10: Training breathing at resonance frequency. Session 4 marked the 
beginning of RFB training. I began by setting the pacer to the breathing rate determined in the 
previous session. Next, I reinforced low and slow diaphragmatic breathing while the participant 




followed the breathing pacer for 3-recorded minutes. The participant was asked to notice how 
this breathing felt compared to his typical breathing pattern to encourage mindful observance. 
Then, I turned the computer screen away from the participant and asked him to practice 
breathing without the use of the pacer for 3 recorded minutes. I then paused the recording screen 
and asked the participant to describe his thoughts and feelings about breathing without visual 
feedback and assistance of the biofeedback software. I provided nonjudgmental, encouraging 
feedback about the participant’s breathing practice before revealing his performance on the 
computer monitor. 
 The client was asked to breathe with the pacer for another 3-recorded minutes before the 
computer monitor was turned away from his visual field. These steps were repeated until the 
participant was able to breath within one half breaths of his resonance frequency pattern. 
Switching between paced breathing and independent practice allowed for the participant to 
gradually learn breathing at his resonance frequency. Sessions 4-10 were devoted to training 
breathing at resonance frequency with a combination of both paced and independent breathing. 
The breathing pacer was utilized as a guide until the participant is able to breath within one half 
breath of his resonance frequency. The ratio of paced-to-independent breathing was adjusted 
based on participant’s performance. The client was asked to breathe with no feedback or pacer 
when he was able to breath at the desired frequency and repeat until this frequency was 
sustained. Please refer to Appendix G for a session-by-session outline of goals, activities, and 
measures. 
At-Home Breathing Practice 
 A component of the RFB protocol is at-home diaphragmatic breathing practice. The 
participant was asked to practice and record (on the Migraine Log) two 10-minute diaphragmatic 




breathing sessions per day (Khazan, 2013). This homework was assigned after Session 3 and 
throughout treatment once the participant’s RFB pattern was determined. The participant was 
provided with a reference to a free breathing pacer application available on smartphones.  
At-home practice is a crucial component to this protocol and was practiced both in the absence of 
migraine symptoms and when symptoms began to develop (Gauthier, Cote, & French, 1994).  
At-home practiced was also strongly suggested to ensure that breathing skills and changes in 
symptomology were accurately measured during the 3-month follow-up outcome assessment. 
Migraine Logs 
 A daily migraine log is both a measurement of symptoms and a means of data collection. 
The Migraine Log and Descriptive Migraine Log helped me and participant organize the 
following variables: (a) pain level, (b) frequency of symptoms, (c) consumption of alcohol and 
caffeine, (d) use of migraine medication, and (e) diaphragmatic breathing practice. These are all 
important factors that can affect migraine symptoms and were importance areas of discussion 
between me and the participant. 
Follow-Up Assessment 
 The behavioral clinical trials workgroup under the auspices of the American Headache 
Society suggests a 3-month follow-up outcome assessment to determine maintenance of 
treatment gains (Penzien et al., 2005). Therefore, the participant was contacted via telephone 
and/or email by me at the end of each month for a total of three months and asked about current 
migraine symptoms and their effect on his quality of life. The participant was instructed to 
continue the daily breathing exercises and fill out the migraine symptom logs so that data can be 
properly recorded and reported. I collected and scanned copies of migraine logs sent from the 
participant via email each month in addition to administering the MSQ 2.1 to assess for changes 




in quality of life.  
Data Analysis 
 This study aimed to measure the effects of HRV on migraine symptoms through a 
biofeedback protocol. Both HRV and migraine symptoms were dependent variables and the RFB 
breathing protocol was the independent variable. The data was analyzed using an AB single-case 
design that included a baseline phase, with repeated measures throughout the protocol, and 
follow-up assessment. Continuous measurement of the dependent variables through biofeedback 
allowed for comprehensive assessment and visual observation of phase changes in the data. Data 
analysis in single-case designs was accomplished through visual inspection of information, 
namely the dependent variables and physiological signals displayed in biofeedback (Engel & 
Schutt, 2008).  The behavioral clinical trials workgroup under the auspices of the American 
Headache Society supports the use of single-case experimental designs for evaluating behavioral 
therapies (Penzien et al., 2005). 
 I analyzed graphed data after each session and observed the effect of the protocol on the 
dependent variables. Continuous and repeated analysis of visual data allowed for observation of 
variables and what shifts occurred in comparison to baseline measurements (Barnett et al., 2012). 
Utilizing an AB single-case design allowed for visual inspection of phase changes in the 
dependent variables through continuous and repeated measures. Additionally, I compiled and 
organized data from the migraine logs completed throughout the baseline phase, biofeedback 
protocol, and follow-up period of the study. This data was organized into graphs and tables so 
that changes in migraine frequency and variables associated with migraine headaches could be 
analyzed. 
 




Rationale for AB Single-Case Design 
 Utilizing an AB single-case design focuses on the clinical significance of an intervention 
and views variability as important data, not as error (Barlow, Blanchard, Hayes, & Epstein, 
1977). This focus on intrasubject variability is necessary in biofeedback research as both baseline 
measurements and phase changes differ between individuals. Single-case designs, also known as 
systematic case studies, are easy to utilize in clinical situations and respond to the subjective 
nature of human physiology (Barlow et al., 1977). This design was the most appropriate for the 
study because it involved repeated measurement and visual analysis of data that is responsive to 
the subjective characteristics of each participant. 
Magnitude of Effect 
 The goal of using an AB single-case design was to find clinical rather than statistical 
significance. Repeated measures of the participant and changes in data highlight the magnitude 
of change (Barlow et al., 1977). The dependent variables and other physiological variables differ 
between individuals; therefore creating a threshold for significance would be contraindicated. 
Therefore, the participant served as his own control in this study. This study focused on the level 
and trend of the data to determine the magnitude of effect. The level refers to the amount of 
change since the intervention and the trend refers to the direction of the data points (Engel & 
Schutt, 2008). Examining graphed data allowed the researcher to visually inspect changes in the 
data (level and trend) and compare it with baseline recordings. 
 The study aimed to increase HRV and decrease migraine symptoms and assess 
physiological functioning through adjunctive measures (i.e., heart rate, skin conductance, and 
finger temperature). Overall change was determined by the following: (a) the participant’s ability 
to breathe within one half breath of his resonance frequency, (b) an increase in HRV, and (c) a 




decrease in migraine symptoms. This was assessed through daily migraine logs and graphed data 


























Chapter 4: Results 
 This section reviews results from a single participant’s involvement in a biofeedback 
protocol hypothesized to increase HRV and decrease the frequency of migraine symptoms. The 
participant completed the following as part of the study: (a) migraine logs to establish a  
two-week baseline of symptoms, (b) 10 weekly biofeedback sessions aimed at increasing HRV 
through RFB, (c) weekly symptom logs to track changes in migraine frequency throughout the 
protocol and 3-month follow-up phase, (d) daily at-home breathing practices, (e) a migraine 
symptom questionnaire (MSQ 2.1) administered monthly throughout the study, and (f) three 
follow-up assessments (via telephone and/or email) to collect symptom logs, administer the 
MSQ 2.1, and assess for changes in migraine frequency and adherence to breathing exercises. 
Participant Demographics 
 The participant’s primary care provider handed him the study’s recruitment letter and 
encouraged him to seek out adjunctive and/or alternative interventions to manage his migraine 
symptoms. Demographic details are reviewed to provide information pertinent to the 
participant’s presenting problem and other factors that impact this applied research study. The 
participant’s identifying information is kept confidential and all information has been adjusted to 
ensure confidentiality. The demographic and personal information reviewed are important 
factors that bolster the discussion of the role that individual and environmental factors can play 
in the experience of migraine headache. 
 The participant, “Michael,” is a 28-year-old Asian American male with a history of 
migraine headaches. He is an anesthesiology resident in Boston, Massachusetts and reported 
significant stress related to his occupational tasks and demanding schedule. He routinely reports 
migraine symptoms to his primary care provider and is unable to find a sustainable intervention 




that alleviates his suffering. He was interested in learning a non-pharmacological approach to 
help manage the intensity and frequency of his migraine episodes. 
History of Migraine Symptoms 
 Michael’s history of migraine without aura symptoms was gathered through the MST and 
interview during the post-screening meeting.  He reported experiencing at least five migraine 
headaches per month (i.e., “Yes, at least five migraines.”) that can last between 4 and 72 hours 
per attack. Michael was unable to estimate an approximate duration for a typical headache, but 
indicated that the pain persists in different intensities throughout a day. He reported that the pain 
is unilateral, pulsating, and moderate to severe in intensity. Michael also experiences nausea, but 
denied vomiting due directly to a headache. Michael reported that his migraines are distinct from 
other medical disorders. He denied problems initiating and maintaining restful sleep and sleeps 
an average 6-7 hours per night. Michael has experienced migraine headaches for several years 
and his symptoms (e.g., frequency of attacks, location of pain, etc.) have been generally stable 
for over 6 months. These reported symptoms fulfill inclusion criteria and qualified him for the 
study. 
He routinely takes Advil or Tramadol during headache episodes to decrease the pain and 
duration. Michael reported inconsistent effectiveness of these medications. He expressed a desire 
to learn a potentially effective behavioral intervention to decrease his reliance on medications. 
Michael was interested in engaging in the biofeedback protocol and learning ways to potentially 
manage his migraine headaches.  
Two-Week Baseline Period 
 The study utilized a two-week baseline period to assess the pattern of migraine without 
aura symptoms. This baseline period adheres to the guidelines for trials of behavioral treatments 




for recurrent headache outlined by the American Headache Society Behavioral Clinical Trials 
Workgroup (Penzien et al., 2005). Michael reported 3 distinct migraine episodes over the 
baseline period. Each episode lasted approximately one hour and had a mild to moderate pain 
intensity (3/10 on ascending Likert pain scale). Michael indicated that he has lingering pain 
following the migraine, but experiences the most intense pain for approximately one hour. The 
situations and events surrounding the migraines included waking up in the middle of the night to 
respond to an on-call request; getting ready for work; and rounding on patients while at work. 
Michael reported bilateral, left-sided head pain, photophobia, nausea, and myalgia. He took 
medication during each attack and indicated that the pain decreased after administration of 
medication. 
 Michael reported that his migraines typically follow work-related stress. The situation 
and events of the migraines during the baseline phase reflect the possible effect of his work 
environment on migraine frequency. At the same time, Michael denied any clear prodromal 
symptoms that signal the onset of his migraines. He stated that his work environment is 
inherently stressful (surgery department in a large, metropolitan hospital) and it is difficult for 
him to determine what specific events at work trigger migraines. The baseline phase allowed 
both researcher and participant to discuss the role that his occupation might play in migraine 
symptoms. We reviewed the possible role that HRV biofeedback can play to help moderate his 
response to work-related stress. 
HRV Biofeedback Protocol: Determine RFB 
 The goals and activities of Sessions 1-3 were to gain measures of Michael’s baseline 
physiological functioning, teach and practice diaphragmatic breathing skills, and determine his 
resonance frequency breathing pattern. Please refer to Appendix G for a detailed outline of 




Sessions 1-3. These sessions helped orient Michael to the pace and structure of the biofeedback 
protocol and allowed for rapport building with the biofeedback administrator. Sessions 1-3 were 
framed as skill builder sessions for Michael to become aware of his baseline physiological 
signals and increase his insight into his migraine symptoms and frequency through the migraine 
logs. Each biofeedback session begins with a 2-minute baseline period followed by 15 minutes 
of data collected to record autonomic activity. Sessions 1-3 are specifically addressed as they 
have different goals and activities. 
 Session 1. This session began with teaching basic diaphragmatic breathing skills with 
Michael’s participation. Michael has previous experience with relaxation breathing practices, but 
found that he needed to focus on the rising and falling of the stomach, rather than the movement 
of his chest. Michael responded well to diaphragmatic breathing and was able to take low and 
slow breaths and find a relaxed, seated posture. He practiced breathing for approximately 15 
minutes as the biofeedback software measured his baseline activity. Michael utilized the rising 
and falling of the breathing belt as a measure of breathing (e.g., watching the belt move with his 
breathing). 
 Baseline measurement for Michael’s autonomic activity was measured as he practiced 
diaphragmatic breathing. The biofeedback software indicated that Michael was very responsive 
to the relaxing effects of autonomic breathing on the autonomic nervous. His heart rate, HRV, 
skin conductance, and finger temperature all reflected a strong ability to regulate his autonomic 
nervous system (see Table 2). His HRV (24.49) and finger temperature (92.63°F) were especially 
strong. These measures were so strong that there would hypothetically be little increase in these 
variables due to such a robust measurement at baseline. Michael’s high, low frequency reading 
(0.96 hz) reflected a strong baroreflex and ability to balance sympathetic and parasympathetic 




activity. His high frequency (.05 hz) and very low frequency (.71 hz) readings were of additional 
importance to measure baseline parasympathetic and sympathetic activity, respectively. 
Moreover, Michael was already comfortably breathing an average of 5.6 bpm, a frequency 
within the anticipated resonance frequency range. Michael was prepared to practice paced 
breathing during the next session and begin the process of determining his RFB pattern. 
 Session 2. The focus of Session 2 was to practice paced breathing set to his baseline 
breaths-per-minute (6.0 bpm). Michael’s breathing pattern was already within the RFB range 
(4.5 -7 bpm). Therefore, we did not have to work on decreasing his breathing frequency. This 
allowed us to strengthen his current breathing skills and capacity to breathe within the RFB 
range. Michael continued to breathe with low and slow diaphragmatic breaths and often watched 
the rise and fall of the breathing belt. 
 There were significant phase changes between Sessions 1 and 2, specifically in heart rate 
and HRV. Michael’s heart rate during Session 2 (87.98 beats-per-minute) increased by 18.87 
beats-per-minute compared to his baseline measure during Session 1 (69.11 beats-per-minute). 
His low frequency (1.0 hz), very low frequency (1.44 hz), and high frequency (.29 hz) readings 
are consistent with increased heart rate and autonomic arousal compared to Session 1. Michael’s 
average HRV decreased by approximately 10 points, which indicated less variability of his heart 
rate within breath cycles (max-min averages). His average HRV in Session 2 (14.22) was still in 
a healthy range (>10), but significantly decreased compared to baseline. At that point it was 
unclear whether Session 1 or Session 2 was an outlier. Michael indicated that his increased heart 
rate might be attributed to the added stress of following a breathing pacer. The increase of his 
very low frequency reading (.05 hz to 1.44 hz) reflects increased sympathetic activation and is 
consistent with this stress hypothesis. He reported feeling more comfortable breathing on his 




own and felt a pressure to follow the rise and fall of the pacer. We reviewed the importance of 
adhering to the breathing pacer to ensure that his breathing follows a set frequency. 
 Session 3. Session 3 was dedicated to determining Michael’s RFB pattern and using this 
pattern as part of his breathing exercises throughout the biofeedback protocol and at-home 
breathing practices during protocol and follow-up phases. This session began with Michael 
breathing at 7 bpm and gradually decreasing his bpm by .5 breaths every 3 minutes. He was 
allowed 1 minute of adjustment between changes in breathing frequency and his autonomic 
activity was recorded for 2 minutes (for a total of 3minutes of breathing at each frequency). 
Michael was instructed to breath with a visual pacer on the computer monitor as the biofeedback 
software measured his autonomic activity. Data was organized on the Resonance Frequency 
Breathing Rate Determination Table  (see Table 1) and indicated that his RFB pattern was 5.5 
bpm based on the strength of his low frequency reading, max-min HRV, and smoothness and 
synchronicity of his heart rate and RSA (respiratory sinus arrhythmia). Michael was also asked 
about what period breathing felt most natural and comfortable. Michael reported that 5.5 bpm 
and 4.5 felt like the most comfortable natural paces. The remainder of the protocol focused on 
training Michael’s breathing at his resonance frequency pattern to work towards increasing his 












Resonance Frequency Breathing Rate Determination Table 
Breathing Rate 




Max-min HRV Heart Rate (Rate 
smoothness and 
regularity of HR 
on scale of 1-5) 
RSA (Estimate 
synchronicity of 
heart rate and 
breath on scale of 
1-5) 
7.0 bpm .7 24.2 
 
3 3 
6.5 bpm .7 24.5 3.5 4 
6.0 bpm .8 24.2 4 
 
4.5 
5.5 bpm 1.0 32.2 4 5 
5.0 bpm .9 23.4 4 3.5 
4.5 bpm 1.0 25.1 3 3 
Note. Resonance frequency breathing rate determination template. Adapted from The Clinical 
Handbook of Biofeedback: A Step-by-Step for Training and Practice with Mindfulness  





 Weekly migraine logs. Michael documented 4 migraine episodes between May 31st and 
July 4th, 2014 (see Figure 1). The length of the attacks ranged from 3-5 hours, with the 5-hour 
episode causing the most pain. The pain ranged from 3-5 out of 10 and was overall described as 
“throbbing, bilateral, and achy.” Michael took migraine medication during the migraine episodes 
that he believed decreased the length of the attack. Michael reported that his migraine episodes 
started when he woke up for work and was “stressed” about work-related tasks. He also reported 
that a migraine began in preparation for an overseas trip, an event that involved stressful 
preparation. Lastly, he was confused when a migraine began while at a coffee shop. He reported 
that migraines typically begin in the context of a stressful event and was unaware what triggered 
the episode at the coffee shop. We collaboratively reviewed the growing relationship between 
work-related stress and his migraine episodes. 




HRV Biofeedback Protocol: Training Breathing at Resonance Frequency 
 Sessions 4 through 11 are collectively reviewed as they share similar goals and activities. 
The initial goal was to strengthen Michael’s ability to breathe within .5 breaths of his resonance 
frequency. Each session started with a 2-minute baseline followed by 15 minutes of recorded 
breathing to measure autonomic activity.  Strengthening his breathing coherence was 
accomplished with utilization of the breathing pacer and gradually decreasing use of the pacer 
and verbal feedback of the biofeedback administrator. Moreover, Michael’s coherence to his 
RFB pattern was facilitated by at-home breathing practice with a breathing pacer application on 
his iPhone set specifically to 5.5 bpm. 
 Sessions 4-11: Phase changes. Michael’s breathing coherence, finger temperature, and 
skin conductance all followed the hypothesized trend. Michael’s ability to breathe within his 
resonance frequency was a strong, stable ability throughout the protocol. His average  
breaths-per-minute ranged from 4.75-5.64 across Sessions 4-11. He was able to relax before the 
biofeedback session began and begin the 2-minute baseline phase in a relaxed position prepared 
for paced breathing. Michael’s finger temperature was also a stable measure throughout the 
protocol and ranged between 91.71 and 94.83°F. Michael was able to increase his finger 
temperature minutes into the breathing exercise and sustain a high temperature. This stable, high 
temperature is indicative of decreased sympathetic activity. Lastly, his skin conductance made 
unremarkable changes and all session averages were within normal limits (<5 mc.). This was a 
stable measure and was vulnerable to inconsistent readings that were excluded during data 
analysis. 
 Other autonomic variables had phase changes inconsistent with the hypothesized 
outcomes. First, Michael’s average heart rate had a wide range (71.92 – 90.1 beats-per-minute) 




and increased as the protocol progressed. The RFB protocol is intended to decrease heart rate as 
the participant increases his/her amplitude of heart oscillations through longer, slower breaths. 
Second, Michael’s HRV did not show a gradual increase throughout the protocol as expected. 
Rather, his HRV ranged between 18.73-14.41 and showed less variability of his heart rate within 
breath cycles. His low frequency trend did not follow an upward trend as hypothesized and 
slightly decreased from baseline to completion of the protocol. Overall, phase changes in 
Michael’s heart rate and HRV did not appear to fit with the phase changes witnessed with other 
autonomic variables and breathing coherence. 
 Potential confounds. There were obstacles during Sessions 4-11 that are important to 
mention for the purposes of this applied research study. Michael arrived for Session 5 and 
reported having a “cold” and experiencing rhinorrhea and congestion. He completed the 
biofeedback session, but needed frequent breaks to blow his nose, sneeze, and cough. The data 
points were erratic and invalid measures of his typical autonomic functioning. For example, his 
frequent coughing caused inconsistent and unstable heart rate readings (85-244 beats-per-minute) 
that were incongruent with data gathered in previous sessions. The data gathered during Session 
5 was not used for analysis and an additional session was scheduled at the end of the protocol. 
 Skin conductance was the only measure that appeared vulnerable to software 
malfunction. Readings during Session 4 and Session 10 were extremely high due to an 
unspecified problem with the sensor. These data points were not included in analysis, but are 
included in the appropriate table and figure to illustrate their inconsistent reading. The 
biofeedback administrator was unable to find the software error and the skin conductance sensor 
produced correct, reliable readings following the session with two individuals unrelated to he 
study. These obstacles were an expected occurrence given the unpredictable nature of behavioral 




interventions. The key in overcoming these obstacles was collaborative communication between 
the biofeedback administrator and participant about rescheduling sessions and correcting for 
errors. 
 Increasing independent RFB. One goal of the RFB protocol was gradually increase 
Michael’s ability to independently breathe at, or within, 0.5 breaths of his resonance frequency. 
Michael showed strong coherence to his RFB pattern during Session 4-7 and agreed that he was 
ready to begin decreasing visual feedback (i.e., the breathing pacer) and verbal reinforcement. 
Session 8-11 worked towards increasing his breathing independence depending on the strength 
of his performance. Session 8 began with paced breathing and then the pacer was removed from 
sight (e.g., laptop screen was turned away from Michael’s vision). The administrator continued 
to provide verbal feedback (e.g., “Keep breathing just as you are.” or “Increase your breathing 
just a bit.”) without the visual cue until all forms of reinforcement were removed. Michael 
performed well and we increased the difficulty into Session 9. Michael was not provided visual 
feedback past the 2-minute baseline and only received periodic verbal instructions during a  
15-minute time period (e.g., “You can increase your breathing rate slightly if it feels 
comfortable.”). Michael breathed independently without any feedback during Sessions 10 and 11 
after the 2-minute baseline. His breathing rate was 5.4 bpm during these sessions and indicated a 
strong coherence to his designated RFB pattern. 
 Weekly migraine logs. Michael documented 5 migraine episodes between July 5th and 
September 19th, 2014 (see Figure 1). The length of the attacks ranged from 30 minutes-2 hours, 
with the 2-hour episode causing the most pain. The pain ranged from 3-4 out of 10. The pain 
descriptions were more diverse than the data gathered during Sessions 1-3. Michael continued to 
experience some attacks that were “bilateral, dull, achy, and on the left side.” Two attacks 




appeared different than the others and were experienced as “sharp.” Overall, the frequency, and 
duration of Michael’s migraine headaches decreased throughout the protocol. Michael took 
migraine medication during 3 of the 5 migraine episodes and expressed an interest in gradually 
utilizing the breathing exercises as an intervention, rather than the medication. The possible 
migraine triggers continued to focus around work-related stress and during the early morning 
hours while he was either on-call or getting ready for work. 
 
Figure 1 
Overall Changes in Migraine Frequency 
 
  
Summary of Phase Changes 
 A goal of this AB single-case design was to observe phase changes in physiological 
variables measured by the biofeedback software during the RFB protocol. The magnitude of 


























Months Involved in Study 




completion of the protocol. This study aimed to find how much and in what direction did these 
variables change in response to the HRV biofeedback protocol. Visual inspection of graphed 
data calculated by the J&J Engineering biofeedback software was the primary method of 
analyzing data. HRV is the focal, dependent variable in this study and its phase change is of 
primary interest. However, the additional physiological signals are important indicators of 
autonomic activity and potential correlates to migraine symptomology. Refer to Table 2 for a 
summary of session averages for each physiological variable measured throughout the protocol. 
 Heart rate. Michael’s heart rate increased from baseline to completion of the study, from 
69.11 to 80.0 beats-per minute respectively (see Figure 2). The biofeedback protocol was 
designed to decrease Michael’s heart rate as he decreased his breaths-per-minute with low and 
slow diaphragmatic breathing. Michael’s heart rate underwent a relative level shift throughout 
the study and increased from baseline with some variability in-between Sessions 4 and 11. This 
















Phase Changes in Heart Rate (Session Averages) 
 




HRV. Michael’s HRV decreased from baseline to completion of the study. The RFB 
protocol was specifically designed and validated to increase HRV, which makes the level and 
trend of this data an unexpected outcome. The study hypothesized that the biofeedback protocol 
would increase his HRV. Instead, the opposite was found. Michael’s baseline HRV was high 
(24.49) and was significantly lower at the end of the protocol (14.94; see Figure 3). These 
findings indicate that there is less variability in his heart rate during averaged breath cycles, 
despite sustained practice of diaphragmatic breathing. His high baseline reading was an outlier in 
the study and his HRV occupied a 4-point range between Sessions 2 and 11. This 4-point range 




























                 





Phase Changes in Heart Rate Variability (Session Averages) 




 BPM. Michael maintained coherent breathing throughout the protocol. He breathed 
within 0.5 breaths of his resonance frequency pattern with the exception of one session (Session 
9, averaged 4.75 bpm). Figure 4 illustrates his stable coherence to his RFB pattern during the 
protocol. Michael was skilled at following both the breathing pacer and breathing without visual 
or verbal feedback. The level and trend of this data adhered to the study’s hypothesis and likely 










































            





Phase Changes in Breaths-Per-Minute (Session Averages) 
 




 Skin conductance. Michael’s skin conductance stayed fairly stable from baseline to 
completion of the study. This was often an unstable measure due to software error, but 
nonetheless had enough data points to show a steady decrease throughout the protocol with a 
slight increase at the last session. Skin conductance was the most temperamental measure in this 
study and was likely affected by the humidity of the study environment and/or outside weather. 
Figure 5 illustrates the two significant outliers during the study and their contrast with other 
measurements of skin conductance. Overall, the level and trend of this variable did not 






























            





Phase Changes in Skin Conductance (Session Averages) 




 Finger temperature. Michael’s finger temperature increased from baseline to 
completion of the protocol from 92.63 to 94.31°F, respectively (see Figure 6). There was a small, 
upward trend in this variable, but there was little room for increase compared to baseline. The 
goal was to increase his finger temperature above 90°F, and if possible, to 95°F. Michael’s 
average finger temperature at Session 11 nearly hit the ceiling of this study and remained a 




























    





Phase Changes in Finger Temperature (Session Averages) 
 




 Autonomic frequencies. The frequencies measured by the biofeedback software 
indicated baroreflex (low frequency), sympathetic activity (very low frequency), and 
parasympathetic activity (high frequency). Overall, the low frequency reading decreased 
throughout the protocol, but was still a modest indicator of baroreflex sensitivity (see Figure 6). 
This value was hypothesized to increase (i.e., sustain a reading of approximately 1.0 hz) during 
the protocol, but its slight decrease is consistent with the downward trend heart rate and HRV 
readings. A more robust increase in baroreflex was expected, but not found in this study. The 
very low frequency reading markedly decreased from baseline to completion of the protocol (see 
Figure 8). This is an encouraging finding as the decreasing trend shows lower activation of the 
sympathetic nervous system compared to baseline. This indicates that the protocol positively 


























         




responses). This decrease in sympathetic activation positively impacted Michael’s ability to 
increase his finger temperature throughout the protocol. Lastly, Michael’s high frequency 
reading slightly increased from baseline to Session 11 (see Figure 9). This upward trend 
indicates that Michael is better able to engage his parasympathetic nervous system and mediate 
stress responses. The high frequency reading gradually declined following Session 7, but was 
hypothesized to continue an upward trend. Overall, I hypothesized a more robust increase in high 
frequency activity from baseline to Session 11. 
 
Figure 7 
Phase Changes in Low Frequency (Session Averages) 
 
































Phase Changes in Very Low Frequency (Session Averages) 
 









































Phase Changes in High Frequency (Session Averages) 
 














































             






HRV Biofeedback Protocol (Session Averages) 
 
  Ses. # Heart 
Rate  
















1 69.11 24.49 5.96 2.23 92.63 0.96 0.71 0.05 
2 87.98 14.22 6.85 8.86 94.26 1.0 1.44 0.29 
3 Refer to Table 1 
4 90.1 18.73 5.64 11.54* 93.6 1.02 .66 .13 
5 No data collected due to participant illness 
6 84.02 15.5 5.18 1.04 91.71 0.79 0.63 0.07 
7 89.73 16.54 5.4 0.89 92.89 0.97 0.93 0.14 
8 71.92 14.41 5.06 0.99 89.36 0.67 0.48 0.09 
9 75.15 16.58 4.75 1.0 92.75 0.78 0.41 0.07 
10 83.51 17.68 5.4 12.72* 94.83 0.9 0.59 0.07 
11 80.0 14.94 5.44 2.26 94.31 0.71 0.46 0.07 





Impact of Other Variables on Migraine Headache 
Alcohol. Michael’s alcohol intake during the study was not associated any recorded 
migraine episodes. More specifically, Michael’s recorded intake of alcohol was not proximal to 
any migraine attack or symptoms. He drank approximately 1-2 times per week and consumed 1-
3 drinks in one sitting. Michael denied any significant alcohol use during the post-screening 
meeting. He routinely drinks socially with co-workers after overnight shifts and reported a “very 
low tolerance” for alcohol. Michael reported feeling “dehydrated” with a “mild headache” during 
Session 4 due to alcohol intake the previous evening. Otherwise, Michael’s alcohol intake did 
not appear to have significant impacts on the study or have an association with his migraine 
symptoms. 




 Caffeine. Michael’s caffeine daily caffeine intake was a stable variable and not 
significantly associated with documented migraine episodes, Association was determined by 
observing the relationship between his migraine episodes and their proximity the presence or 
absence of caffeine use. Michael consumed 1-3 caffeinated drinks (coffee) per day between the 
morning and early afternoon hours. Michael denied using caffeine to ameliorate migraine 
symptoms and described his caffeine intake as a socialized aspect of his routine that keeps him 
alert and engaged during long work days and schedules. Michael only abstained from caffeine 
use for one day throughout the study due to a significant migraine episode that impacted his 
typical functioning. Of note, Michael’s typical ingestion of caffeine prior to biofeedback sessions 
might have impacted changes in HRV. Acute caffeine intake has been found to decrease HRV 
(Sondermeijer, van Marle, Kamen, & Krum, 2002), but typically does not impact heart rate. 
However, heart rate was impacted during the protocol, indicating that other variables impacted 
his decrease in HRV. The impact of caffeine on HRV should is still considered a potential 
variable that impacted phase changes in HRV, but a robust relationship cannot be drawn with the 
current data. Overall, the presence of migraine symptoms did not appear to impact his regular, 
daily consumption of caffeine. 
 Medication. Michael utilized migraine medication only during migraine attacks. He 
denied taking migraine medication in the absence of migraine symptoms. Michael typically took 
1-3 doses of medication per migraine episode, depending on the length of the attack and pain 
level. He took 400mg of Ibuprofen for shorter migraine episodes with mild pain. Michael took 
50mg of Tramadol if migraine attacks “started off badly.” He denied any dependence on or 
significant side effects from the medication. He utilized migraine medication during 83% (10/12 
migraine episodes) of migraine attacks during the protocol (two-week baseline through Session 




11). Michael expressed a hope that continued breathing practice at 5.5 bpm would help him 
decrease his need for medication. His use of medication during the protocol period was stable 
and used for relief during migraine episodes. 
At-Home Breathing Practice 
 At-home breathing practice was a crucial component to strengthen Michael’s 
diaphragmatic breathing skills and adherence to the RFB pattern. The study utilized a free 
smartphone application that allows the user to set approximate breaths-per-minute and time 
breathing practices. Michael was asked to practice 2, 10-minute breathing exercises to strengthen 
the skills learned during the protocol.  He felt unable to set aside 2 separate practice sessions per 
day due to his unpredictable work schedule. We agreed that practice once per day for 15 minutes 
was an achievable daily task that allowed enough time for him to strengthen his paced breathing.  
 Michael began daily breathing practices following the determination of his RFB pattern 
(5.5 bpm). He had an 83% compliance rate according to his documented breathing practices. 
Michael reported that changes in his work schedule and migraine pain negatively impacted his 
ability to practice every day during the protocol. Overall, his high compliance rate appeared to 
help Michael with paced breathing during biofeedback sessions. Moreover, continued practice at 
the same pace allowed Michael to acclimate to and normalize his RFB pattern to facilitate his 
ability to independently breathe without visual feedback. Michael commented that the daily 
breathing practices allowed him to take time to relax, sit with his thoughts, and feel more 
connected to his bodily cues and sensations. 
Follow-Up Assessments 
 The objectives of three monthly follow-up assessments were to collect data from 
migraine symptom logs to assess changes in migraine headaches and adherence to breathing 




practices. An additional component was to offer as-needed consultation and support. This 
typically materialized as periodic emails checking-in about changes in migraine frequency and 
reminders about the importance of daily breathing exercises. The follow-up phase was from 
September 20th, 2014 until December 12th, 2014. 
 Michael reported four migraine headaches during the 3-month follow-up phase. He 
elected to take medication only during one of the migraine episodes. He reported that he is 
working to increase his utilization of diaphragmatic breathing, rather than medication, to help 
decrease his migraine pain. Overall, Michael’s frequency of migraines decreased from baseline 
to the end of the study. He reported 2-3 migraine episodes per month during the study and 1 
episode per month during the follow-up assessments. Overall, Michael reported a decrease in 
migraine frequency that was sustained for three months post-protocol. Michael continued to 
engage in daily, paced breathing practices during the follow-up phase of the study. His 
compliance rate decreased to 74% (compared to 83% during the study) over the 3-month  
follow-up phase. Michael reported that he had some difficulty adhering to daily breathing 
practice after the last biofeedback session. Daily symptom logs indicate that Michael typically 
practiced one, 15-minute breathing exercise between the hours of 3pm and 8pm. He commented 
that continued breathing practice post-biofeedback protocol helped him remain mindful of his 
migraine headaches and engaged in the study. 
 The MSQ 2.1 assessed the impact of migraine headaches on Michael’s quality of life at 
monthly increments throughout the protocol and follow-up phase. The following section outlines 
changes in the MSQ 2.1 domains and its significance for the study. 
Impact of Migraine on Quality of Life 
 The MSQ 2.1 is a 14-item instrument used to measure the impact of migraine headaches 




on Michael’s quality of life during the study. The MSQ 2.1 was administered during Sessions 1, 
5, and 10 and during the 3-month follow-up period. The MSQ 2.1 measured the impact of 
migraine symptoms every four weeks within three distinct dimensions: (a) role function 
restrictive (RR), (b) role function preventive (RP), and (c) emotional function (EF). Michael 
answered each item according to a 6-point Likert scale and the raw total was transferred to a  
0-100 point scale. Larger scores indicate a better quality of life and help to describe changes in 
the subjective impact of migraine throughout the study. Overall, the phase changes in dimension 
scores reflect a significant decrease in the negative impacts of migraine headaches on Michael’s 
quality of life. 
 Role function: Restrictive. Michael’s scores in the RR domain had an upward trend 
throughout the study (see Figure 10). His scores from baseline to completion (57.14 – 83.0) 
reflected a marked decrease in the restrictive effects encountered by Michael due to migraine 
symptoms. He reported an increased capacity to: (a) interact with family and friends during 
migraine episodes; (b) engage in leisure activities; (c) perform work tasks; (d) complete 
household tasks/activities; (e) concentrate on work and daily activities; and (f) feel energized and 
able to engage in work. The significant level change (approximately 16 points) indicated that 
Michael feels less restricted by his migraine symptoms and more able to engage in relationships, 
work, and leisure activities.   
 Role function: Preventive. The RP domain maintained a stable trend and indicated that 
Michael does not feel prevented from undertaking and completing work tasks and leisure 
activities. There was a modest decrease in this domain during Session 10 (see Figure 10) and 
indicated that Michael’s functioning was more negatively impacted by his migraine symptoms. 
Michael indicated that his work schedule is demanding and he is rarely able to take days off from 




work, regardless of his migraine symptoms. He typically “works through” his migraine pain 
and/or takes medication. This explanation helps explain the stable, high score within the RP 
domain. Overall, his scores were high and stable in this domain and continued to increase into 
the follow-up assessments. 
 Emotional function. The EF domain had an upward trend and significant level change 
from baseline to the end of the study (40.0 – 87.0). There was a slight decrease in scores during 
Session 1 and the first follow-up assessment (see Figure 10). His scores significantly increased 
during the second and third follow-up sessions and reflect decreased feelings of frustration, 
burdensome to others, and fear of disappointing others. Overall, Michael’s emotional function 



















Overall Changes in MSQ 2.1 Domains 
 
Note. *RFR - Role Function  - Restrictive. **RFP - Role Function – Preventive. ***EF - 
Emotional Function. Sess. - Session Number. FU - Follow-Up Assessment. 
  
 
Relationship Between HRV and Migraine Symptoms 
 The primary objective of this study was to* determine the role of HRV in the treatment of 
migraine symptoms. The major hypothesis was that an increase in HRV, facilitated through 
resonance frequency breathing biofeedback training, would decrease the frequency and intensity 
of migraine symptoms. An additional component of the hypothesis was that the participant 
would be able to utilize behavioral strategies (i.e., diaphragmatic breathing within resonance 
frequency) learned during biofeedback training to decrease autonomic arousal and migraine 













*RFR 57 71 66 69 83 83
**RFP 90 90 80 90 90 95

















hypothesis outlined in this study. Michael’s HRV and frequency of his migraine episodes 
decreased from baseline to Session 11 (see Figure 11). The intensity (pain level) of his migraines 
did not appear impacted by the addition of the HRV biofeedback protocol.  
 Overall, the addition of the biofeedback protocol in conjunction with daily breathing 
exercises decreased Michael’s HRV and his frequency of migraine headaches. Biofeedback 
training had a positive impact on his migraine frequency, but HRV was not found to be a 
variable associated with a decrease in migraine frequency. Therefore, this single-case study did 
not find compelling data that supported a relationship between HRV and migraine headaches. 
The introduction of the biofeedback protocol had a positive impact on other autonomic variables 
associated with increased autonomic regulation and relaxation (i.e., increased finger temperature, 
decreased sympathetic activity, increased parasympathetic activity, and controlled breathing at 
resonance frequency). Moreover, daily breathing practices likely had a role in controlling 
migraine episodes and reinforcing skills learned during the protocol. The mechanism of change 















Changes in Migraine Frequency and HRV 
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Chapter 5: Discussion 
 Migraines are the most common type of vascular headache and affect 28 million 
Americans and impair functioning and quality of life. The prevalence of migraine headaches 
among both adults and adolescent populations reflects a burdensome and debilitating condition 
that affects productivity and wellbeing. The World Health Organization reported migraines as 
one of the world’s most disabling illnesses, which speaks to the need for effective and 
sustainable treatments. The burdensome effects of a migraine headache is not a matter of 
mortality or morbidity, but what constraints and limitations it has on overall functioning. A 
critical barrier to successfully treating migraines is the misperception that migraine headaches 
are not a treatable public health problem. This societal misunderstanding leads to underdiagnosis, 
undertreatment, and continued impairment.  
 This study sought to determine if an increase in HRV led to a decrease in migraine 
symptoms. The biofeedback protocol was comprised of 10, 30-minute sessions that focus on 
RFB determination and training. The research question was addressed using a single-case design 
in which the biofeedback intervention was administered in the context of ongoing monitoring of 
HRV, migraine symptoms, and other significant physiological variables.  
Major Findings 
 This study did not find a clinically meaningful relationship between HRV and migraine 
symptoms. The HRV biofeedback protocol had the following outcomes and impacts for the 
participant: (a) a decrease in the frequency of migraine symptoms, (b) a decrease in the negative 
impact of migraine headaches on his quality of life, and (c) phase changes in select physiological 
signals consistent with an increased capacity for self-regulation, relaxation, and decreased 
autonomic arousal. Overall, RFB training, facilitated through HRV biofeedback, had a positive 




impact on migraine symptoms without increasing HRV. 
 An extensive review of the biofeedback and HRV literature rendered mixed results 
regarding the relationship between HRV biofeedback and changes in HRV. Previous research 
and meta-analyses reviewed in the literature review found HRV biofeedback training increased 
HRV and positively impacted other physiological variables for a range of conditions associated 
with autonomic regulation (Appelhans & Luecken, 2008; Hassett et al., 2007; Lin et al., 2012; 
Prinsloo et al., 2011; Reynard et al., 2011). Other studies found that an HRV biofeedback did not 
increase HRV, but did have positive impacts on autonomic regulation and flexibility. These 
studies are important to reference and discuss as their findings can offer potential support for the 
results of this study.  
 The following studies highlight the positive impact HRV biofeedback has on autonomic 
regulation without significantly altering HRV. Muele, Freund, Skird, Vogele, and Kubler (2012) 
studied the effect of a 12-session HRV biofeedback protocol on decreasing food cravings. The 
authors found that the biofeedback intervention was successful at reducing food cravings, but did 
not change HRV. Therefore, a reduction in food cravings was not associated with an increase in 
HRV. Swanson et al. (2009), as referenced in the literature review, did not find a robust change 
in HRV after 6 sessions of breathing retraining for patients recovering from heart failure. The 
protocol did however positively impact cardiac health and resiliency and allowed the participants 
to strengthen their capacity to engage in modest exercise. Lastly, Whited, Larkin, and Whited 
(2014) studied the impact of HRV biofeedback on changes in HRV utilizing the emWave 
biofeedback device. The protocol focused on positive cognitive and emotional states to facilitate 
autonomic regulation and breathing coherence (i.e., focusing on the heart, deep breathing, and 
producing positive emotions through self-talk). The study did not find a change in HRV and 




concluded that HRV biofeedback, conducted through emWave, did not have a significant impact 
on resting HRV. This study is important to review as it reviews an alternative biofeedback 
intervention aimed to motivate a phase change in HRV. 
 HRV biofeedback has an inconsistent impact on changes in HRV. HRV biofeedback does 
have a positive, therapeutic impact on the autonomic nervous system as found in this study 
among others in the literature. The major findings of this study are supported in other 
biofeedback research and suggest that other, specific mechanisms are positively impacting the 
autonomic nervous system without significantly impacting HRV. The introduction of the 
biofeedback protocol in this study had a positive impact on other autonomic variables associated 
with increased autonomic regulation and relaxation. Moreover, it taught and reinforced daily 
breathing practices that likely had a role in controlling the frequency of Michael’s migraine 
episodes. Overall, this study found that an increase in HRV was not required for other autonomic 
variables to undergo hypothesized phase changes. Rather, the resonance frequency breathing 
protocol created both robust and modest phase changes in autonomic functioning that seemed to 
adjust overall autonomic regulation and response that had a positive impact on migraine 
symptoms.  
Impact of Contextual Variables on the Research Process 
 Individual variables are of crucial clinical importance when analyzing and discussing the 
results of this study. Single-case designs focus on the individualistic and contextual variables of 
each participant (Barlow et al., 1977). There are several significant factors that had a probable 
impact on Michael’s research participation, engagement in the protocol, adherence to at-home 
practice, and ability to incorporate learned skills into his daily life. These variables carry 
significance in single-case research in addition to the practice of biofeedback in clinical settings. 




 Michael reported that his occupation, as a medical resident in anesthesiology, was a 
primary source of stress that impacted his ability to relax. Descriptive accounts on daily migraine 
logs highlighted the connection between work-related stress and migraine attacks. The chronic 
stress associated with his work schedule highlighted the importance of collaboratively discussing 
the importance of taking time out of his day for diaphragmatic breathing practices. Initially, the 
task of two 10-minute daily breathing exercises concerned Michael. He was unsure how he could 
fit breathing practice into his already busy, often chaotic work schedule. We decided to adjust 
the breathing practice schedule to decrease his distress and increase the likelihood of his 
adherence to at-home practice. Michael was confident that he could fit one 15-minute breathing 
exercise into his schedule. This adjustment to the protocol fit Michael’s individual needs and did 
not add additional distress. Michael commented that the daily breathing practice was a helpful 
and often necessary intervention to moderate the impact of stress on his mood. 
 Michael’s educational background helped him to understand and interpret the 
physiological activity displayed by the biofeedback software during his sessions. This facilitated 
conversation after sessions and seemed to strengthen his interest and engagement in the study. 
We also discussed how his knowledge base might impact his ability to engage in the session 
without “judging” his performance during breathing exercises. Michael reported that he initially 
felt “anxious” during the initial sessions and was often distracted by phase changes in variable 
displayed on the computer monitor. We discussed his desire to “be a good participant,” 
especially during the first two sessions of paced breathing. We reviewed the impact that his 
anxiety and vigilance have on his ability to fully engage in the protocol and benefit from the 
relaxing effects of resonance frequency breathing. Michael eventually became less concerned 
about his performance during paced breathing and learned to briefly close his eyes during 




sessions if he became fixated on visual phase changes on the computer monitor.  
 A strength of this single-case design was the ability to attune to the contextual variables 
that impacted Michael’s performance throughout the protocol. We first discussed the potential 
role that HRV biofeedback and resonance frequency breathing could have on his ability to 
moderate work-related stress. Second, we flexibly adapted at-home breathing practices to fit with 
his schedule and strengthen his adherence to the protocol. Third, we were able to take time 
before, after, and in-between each session to communicate about other variables that might be 
impacting his performance in the protocol. Frequent, collaborative discussion appeared to help 
Michael to feel like an active participant in the research that seemed to strengthen his interest and 
engagement throughout the study. Contextual variables had an important impact on this applied 
biofeedback study and were crucial in helping the researcher understand and appreciate the 
individual needs and background of the participant. 
Limitations 
 An important limitation of this study was the single participant sample. A shortcoming of 
the single-case design is that the researcher cannot generalize the results of one participant to 
another individual with a similar clinical profile (Barlow et al., 1977; Engel & Schutt, 2008). 
Therefore, the results of this study do not have statistical power or significance to generalize to 
other populations. This was an expected and inherent limitation of single-case designs as each 
participant acts as his/her own control. The generalizability of this study could have been 
improved with a larger sample size to determine if the HRV biofeedback protocol had similar 
effects on HRV, migraine, symptoms, and other physiological variables. 
 Problems with the reliability of the biofeedback equipment posed limitations of data 
analysis. The wires, sensors, software, and other components of the I-330-C2 Plus 12-channel 




biofeedback device seemed to malfunction twice during the protocol.  This impacted the 
measurement of skin conductance during Session 4 and Session 10 and these skewed data points 
were excluded from analysis. Otherwise, the device measured physiological activity reliability 
and consistently. Regardless, this limitation is helpful to consider when utilizing biofeedback for 
research and/o clinical purposes. The researcher is encouraged to take time before the session 
and test the device on himself/herself to determine if there are faulty connections or artifact 
readings of physiologic activity. This plan will help avoid problems encountered during the 
session with a research participant or client. 
Implications for Future Research 
 The findings of the current study encourage future research of the following topics to 
better understand migraine symptomology and the relationship between migraine and HRV: (a) 
tonic compared stress responses of HRV, (b) the efficacy of HRV biofeedback for increasing 
finger temperature (c) the relationship between sleep disorders and migraine, and (d) 
experimenting with different HRV biofeedback protocol timelines. Overall, these areas address 
questions and topics elucidated by the current study and have important implications for the 
study of migraine headaches through biofeedback interventions. 
 Tonic and phasic measures of HRV. The limitation in the biofeedback literature is the 
changes in both tonic and phasic responses of HRV during biofeedback treatment. The majority 
of research, including the current study, measures the changes in resting, or tonic changes in 
HRV and not how HRV changes during a stressor (Whited et al., 2014). Future studies may 
benefit from measuring the effectiveness of HRV biofeedback in increasing HRV during 
stressors (Maleki et al., 2012b; Wheat & Larkin, 2010). HRV biofeedback protocols could be 
expanded to include additional scripts that gradually expose participants to stressors once he/she 




is able to independently breathe within the resonance frequency pattern. Introducing stressors 
salient to each participant would allow the biofeedback clinician to better assess for the 
participant’s response to stressors and ability to regulate autonomic activity. This addition to an 
HRV biofeedback protocol would help address deficiencies in stress adaptation and recovery. 
 HRV biofeedback and finger temperature. The HRV biofeedback protocol markedly 
decreased very low frequency power (sympathetic activation) and increased finger temperature. 
These findings have positive implications for applying HRV biofeedback interventions to 
increase fingertip temperature and vasodilation without the sympathetic activation often 
observed during initial thermal biofeedback sessions. Thermal biofeedback involves active effort 
in warming hands and facilitating relaxation. Effort, by definition, involves activation of the 
sympathetic nervous system (Khazan, 2013). The HRV protocol utilized in this study appeared 
to access the physiological mechanisms necessary to increase finger temperature without 
requiring active effort and sympathetic activation. Resonance frequency breathing decreased 
sympathetic activity and facilitated dilation of blood vessels and increased peripheral 
temperature. Therefore, future research should consider the role of HRV biofeedback in 
increasing finger temperature without the sympathetic activation typically observed in thermal 
biofeedback. 
 Sleep disorders and migraine headache. There is considerable research that supports a 
robust comorbidity between headache disorders and sleep problems (Freedom & Evans, 2013; 
Karthik, Kulkarni, Taly, Rao, & Sinha, 2012; Menon & Kinnera, 2013; Walters, Hamer, & 
Smitherman, 2014). This relationship was not assessed in the current study because Michael 
denied problems with sleep initiation and maintenance. However, screening for sleep 
abnormalities regardless of reported sleep patterns would likely produce helpful data in assessing 




the relationship between sleep and migraine. Sleep disorders are common in chronic migraineurs 
and there is a paucity of research about the prevalence of sleep disturbances among people with 
episodic migraine episodes (Walters et al., 2014). Poor sleep hygiene can be a trigger for 
migraine headaches and patients with migraine without aura are especially susceptible to 
problems initiating and maintaining sleep (Menon & Kinnera, 2013; Karthik et al., 2012). 
Therefore, future biofeedback interventions for migraine headache would benefit from 
addressing the significance of sleep hygiene for participants. 
 Expanding protocol timelines. Longer and more frequent HRV biofeedback may be 
required to observe significant phase changes in HRV (Muele et al., 2012). Lehrer’s (2007)  
12-session biofeedback protocol for RFB training may require modifications depending on the 
baseline physiological functioning of participants. For example, additional sessions might be 
necessary to build competence at paced breathing and breathing within resonance frequency. 
Moreover, biofeedback participants may benefit from longer sessions to fully engage in 
diaphragmatic breathing and adjust their breathing to resonance frequency. Overall, future 
research may benefit from adjusting protocol timelines to meet the individual needs and 
physiological functioning of participants. 
Conclusion 
 This single-case study examined the relationship between HRV and migraine symptoms. 
A robust relationship was not found between changes in migraine frequency and HRV, but 
meaningful changes in other autonomic variables were observed. While the hypothesis was not 
supported, Michael was able to learn and utilize a self-regulation exercise that did have a positive 
impact on migraine frequency and the impact of migraine on his functioning. A single-case 
design was an appropriate methodology to best understand and assess the impact of contextual 




variables and individual symptoms. Michael experienced throughout the protocol. Behavioral 
studies utilizing single-case designs are more cost-effective than pharmacologic studies that 
require substantial funding and a large sample of participants. Moreover, single-case designs 
focus on the individual to help alleviate behavioral problems that vary between participants (e.g., 
physical pain, anxiety, stress, etc.; Barnett et al., 2012). The single-case approach also fostered a 
strong alliance between me and the participant, which likely had a positive impact on study 
engagement and motivation. Overall, this study highlighted the role and utility that biofeedback 
interventions can play in alleviating a medical condition otherwise treated with pharmacological 
agents. I hope these findings can encourage the use of biofeedback as a valid treatment within 
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Appendix A – Recruitment Letter 
 
Do You Suffer From Migraine Headaches? 
  
Thomas Ledoux, M.S., Inna Khazan, Ph.D., BCB, and Catherine Schuman, Ph.D. are conducing 
a study to determine the effectiveness of a biofeedback protocol on migraine symptoms. 
Biofeedback is a way to help people develop greater awareness and ability to regulate their 
psychophysiological processes by using signals from their own bodies for the purpose of 
improving their health. This recruitment letter is being offered to you because you are 18 years 
of age or older and your health care provider believes you could benefit from this study. 
 
Do you Experience the Following Symptoms? 
• At least 5 headache attacks per month for at least one year 
• Moderate to severe headache pain lasting between 4 and 72 hours that negatively affect 
functioning 
• Do your headache episodes include some of the following symptoms? 
o Pain on one side of your head 
o Pulsating pain 
o Moderate to severe pain intensity 
o Headache pain is aggravated by or causes avoidance of physical activity 
o Nausea and/or vomiting 
o Sensitivity to light and/or sound 
If these symptoms have been generally stable for the past 6 months you may be eligible for 
our study. 
 
If you choose to participate in this study, the study procedure include the following: (a) a 2 week 
baseline period to track and record your migraine symptoms, (b) 10 weeks of weekly 30-minute 
biofeedback visits, and (c) and follow-up assessments that will be conducted over the phone by a 
member of the research team once a month for 3 months. 
 
It is important to know that this letter is not to tell you to join this study. It is your decision. Your 
participation is voluntary. Whether or not you participate in this study will have no effect on 
your relationship with your health care provider or treatment as a patient. 
 
If you are interested in learning more about how to become involved in this study, please contact 
Thomas Ledoux at xxx-xxx-xxxx to review the next step involved in the recruitment process. 
You do not have to respond if you are not interested in this study. 
   




Thomas Ledoux, M.S., Inna Khazan, Ph.D., BCB, and Catherine Schuman, Ph.D. 
 




Appendix B – Migraine Symptom Tool 
 
Migraine Symptom Tool 
 
The following items adhere to the diagnostic criteria for migraine without aura as outlined in the 
International Classification of Headache Disorders (2nd ed.). (Headache Classification 
Subcommittee of the International Headache Society [ICHD-II], 2003) 
 
 
1. Are you currently pregnant, planning on becoming pregnant within the next 5 months, 
or lactating? 
 
 ___ Yes   ___No 
 
 
2. Have you experienced at least 5 headache attacks in the past month? 
 
 ___ Yes   ___No 
 
 
3. Have these headache attacks lasted between 4 and 72 hours? 
 
 ___ Yes   ___No 
 
 
4. Please indicate if you experienced any of the following symptoms during your headache 
attacks within the past month: 
 
 ___Unilateral location (pain on one side of the head) 
 
  
 ___Pulsating quality 
 
 
 ___Moderate to severe pain intensity 
 
 
 ___Headache was aggravated by or caused avoidance of routine physical activity 
 
 
 ___Nausea and/or vomiting 
 
 
 ___Photophobia (sensitivity to light) and/or phonophobia (sensitivity to sound) 
 
 




5. During the time of your headache episodes did you suffer from any medical disorder? 
 
 ___Yes   ___No   Please specify:  
 
 
6. Have you experienced the migraine symptoms for at least one year? 
 
 ___Yes   ___No 
 
 
7. Have your headache symptoms (e.g. frequency of attacks, severity, location of pain, 
other associated symptoms) been generally stable for a period of 6 months or more? 
 






















Appendix C – Informed Consent 
Your Name: ___________________  Date: ________________ 
Date of Birth: __________    Phone Number: ____________________ 








1. Invitation:  
 You are invited to take part in a research study by Thomas Ledoux, M.S., Inna Khazan, 
Ph.D., BCB, and Catherine Schuman, Ph.D. We hope to better understand the effect that heart 
rate and breathing have on migraine headaches. Our goal is to work with several people with 
migraine headaches who are interested in decreasing their migraine symptoms without the use of 
medication. This study involves 10, 30-minute weekly sessions to help decrease migraine 
symptoms and increase healthy breathing patterns. The study also involves 3 monthly follow-up 
phone calls where your migraine symptoms will be reviewed. 
 This study uses a biofeedback instrument to help measure heart rate, breaths-per-minute, 
skin moisture, and finger temperature. The instrument uses small sensors placed to the skin with 
a simple and safe adhesive patch. The biofeedback instrument creates a display on a computer 
screen that helps us better understand your body’s activity during breathing exercises. 
 You have the choice to take part or not. If you take part in the study, you may change 
your mind at any time, and leave the study. If you withdraw from the study, you may also 
remove any of your data we have collected from the study. 
  
2. Purpose for the Study: 
 The purpose of this research is to better understand the relationship between changes in 
heart rate and migraine symptoms. Your heart rate is always changing. A good sign of a healthy 
heart is its flexibility to change. Research shows that greater differences in heart rate are related 
with increased heart health, which makes it an important area of research. Your heart is a muscle, 
and the differences in your heart rate show how “in shape” your heart is to deal with stress, 
excitement, relaxation, and even pain. 
 Taking slow, deep breaths helps increase the differences in heart rate and improve 
relaxation. This study will measure your current breathing pattern and work on teaching new 
breathing patterns that increase your heart’s flexibility. This involves teaching “low and slow” 
breathing and often decreasing the number of breaths you take per minute. We believe that 
adjusting your breathing rate can decrease stress and the number of migraines you experience. 
The goal is to learn your healthiest breathing pattern and determine if breathing at this rate 
improves your heart’s flexibility and decreases migraine symptoms. 
 
 





3. Reasons why you have been selected for the study: 
 You have been asked to participate in this study because you have indicated that you 
experience migraine headaches; other treatments are not effective at decreasing your migraine 
symptoms; and you are interested in learning a possibly helpful behavior that can decrease your 
migraine symptoms. 
  
4. Period of Participation (How long you will be involved in the study): 
 The study involves a 2-week period to track and record your migraine symptoms. 
Additionally, there are 10 weeks of weekly 30-minute visits and 3 monthly follow-up phone calls 
from a member of the research team. 
 
5. Procedures (What we will do):  
 If you decide to take part in this study, we will ask you to take part in the following 
activities:   
(1) Review the study and the equipment (Post-Screening Meeting, 30 minutes)  
 (2) Discuss the effects of migraines on your health 
 (3) Review migraine logs that are completed between sessions 
 (4) Use the biofeedback equipment and understand your breathing pattern (Session 1)
 (5) Determine healthy breathing pattern (Sessions 2 and 3), and continue to practice your 
 healthy breathing pattern (Sessions 4-10) 
 You will be asked to practice 2, 10-minute breathing exercises per day to strengthen the 
skills learned during the study. These practices are in addition to weekly biofeedback visits. Both 
you and the researcher will review migraine logs and the information collected during breathing 
training. This helps you better understand your breathing patterns and how they affect your heart 
rate and migraine symptoms. 
 
6. Possible Risk, Discomforts, Side Effects, and Inconveniences: 
 The biofeedback treatment you will receive does not involve any risk. This study does 
not require you to have any other treatments. This study does not involve any risks that you 
would not face during a regular visit with your primary care doctor. 
 The results and data of this study are for research purposes only. We will be happy to talk 
with you about any questions you have about the study. 
 
7. Alternatives to Participation: 
 You may choose not to participate in this study. 
 
8. Benefits (What good may come from the research) 
 This research may have the following benefits: (a) a better understanding of your 
breathing pattern, (b) learning patterns of relaxed breathing, (c) a decrease in migraine 
headaches, and (d) an understanding of how breathing affects your behavior and body. This 
research may or may not help you directly. However, what we do learn may help others. 
 
9. Costs: 
 You will not have any added costs from being in this study. All study related visits will 
be provided at no cost. 





10. Compensation (Reward for taking part): 
 There is no compensation or reward for taking part in this study, apart from the benefits 
described above.  
 
11. Voluntary Participation: 
 Taking part in this study is voluntary. If you do not take part you will not lose any 
benefits that you have the right to receive.  The quality of your health care will be the same, 
whether you take part, refuse to take part, or decide to leave the study. 
You may choose to take part in this study.  If you choose to take part, then: 
(a) Your participation is voluntary and you may leave the study at any time.  To leave 
you must: 
1. Please contact the primary researcher by email, telephone, or written letter to 
indicate your withdrawal from the study.  
 
12. Privacy/Confidentiality: 
 There are laws (state and national) that protect your health information to keep it private. 
We always follow those laws. We will protect all of your health and personal information. Your 
name and personal information is kept confidential using a unique code to ensure confidentiality. 
 
 If you take part in this study, you agree to let the research team use the information 
gathered during the biofeedback session(s). Do not agree to take part if you don’t want the 
research team to use this information. The research team agrees always to follow these rules:   
• The research team will view your health information only during the life of this study. 
• We will not include any information that could identify you in any published works. 
• At the end of the study, the research team will remove all of your personal 
information (name, address, phone number, etc.) from our database.  
 
13. Period of Authorization: 
 Your authorization on this research project will be collaboratively decided by researcher 
and research participant. 
 
14. Getting Help (Contacts): 
 About the research project:  If you have questions about this study, then you have the 
right to ask for help. You may contact the primary researcher with any questions or concerns. 
 Primary Researcher: Thomas Ledoux, M.S. 
             Graduate student and Doctoral Candidate in Clinical Psychology at       
                                              Antioch University New England 
                                              Contact Number: 603-493-6621 
  
Certification from Person Obtaining Consent: 
The participant has been informed of: 
 (i) The procedure, purpose, and risks of the study as described above, 
 (ii) How his/her health information may be used, shared and reported, and  
 (iii) his/her privacy rights. 
 





The subject has been provided with a signed copy of this form. 
 
 
 _________________________________   ____________________ 




 _________________________________            _____________________ 
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Appendix D – Migraine Log 
  Migraine Log 
 
Name            Date    
 
Instructions 
1. Please fill out this log twice per-day to track your migraine symptoms and (2)     
    daily breathing exercises. 
2. Please describe your experiences during a migraine episode on the Descriptive  
    Migraine Log. 
3. Please use the appropriate symbols to further describe your migraine experience 
4. Please indicate your average pain level during the 24-hour period. 
 
 
 C = caffeinated coffee/tea/sodas A = Alcohol B = Breathing exercises (10-minute sessions) P = Pain M = migraine medication 
 
 
Date  (day 1)
 
Noon 1 PM 2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM 11 PM 12 AM 1 AM 2 AM 3 AM 4 AM 5 AM 6 AM 7 AM 8 AM 9 AM 10 AM 11 AM 
Pain 
Level 
                                                  
 
Date  (day 2)
 
Noon 1 PM 2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM 11 PM 12 AM 1 AM 2 AM 3 AM 4 AM 5 AM 6 AM 7 AM 8 AM 9 AM 10 AM 11 AM 
Pain 
Level 
                                                  
 
Date  (day 3)
 
Noon 1 PM 2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM 11 PM 12 AM 1 AM 2 AM 3 AM 4 AM 5 AM 6 AM 7 AM 8 AM 9 AM 10 AM 11 AM 
Pain 
Level 
                                                  
 
Date  (day 4)
 
Noon 1 PM 2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM 11 PM 12 AM 1 AM 2 AM 3 AM 4 AM 5 AM 6 AM 7 AM 8 AM 9 AM 10 AM 11 AM 
Pain 
Level 
                                                  
 
Date  (day 5) Noon 1 PM 2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM 11 PM 12 AM 1 AM 2 AM 3 AM 4 AM 5 AM 6 AM 7 AM 8 AM 9 AM 10 AM 11 AM 
Pain 
Level 
                                                  
 
Date  (day 6)
 
Noon 1 PM 2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM 11 PM 12 AM 1 AM 2 AM 3 AM 4 AM 5 AM 6 AM 7 AM 8 AM 9 AM 10 AM 11 AM 
Pain 
Level 
                                                  
 
Date  (day 7)
 
Noon 1 PM 2 PM 3 PM 4 PM 5 PM 6 PM 7 PM 8 PM 9 PM 10 PM 11 PM 12 AM 1 AM 2 AM 3 AM 4 AM 5 AM 6 AM 7 AM 8 AM 9 AM 10 AM 11 AM 
Pain 
Level 
                                                  
 
 
 No Symptoms 
  
/ Prodrome Symptoms 
  
 Migraine Pain 
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Appendix E – Descriptive Migraine Log 
Descriptive Migraine Log 
Please document your migraine symptoms to the best of your ability on the following table. 
 
Descriptive Migraine Log 
Date and Time Situation/Event Possible Triggers Intensity of Pain 
(1-10) 
Symptoms 
     
     
     
     
     
     
Note. Descriptive migraine log. Adapted from The Clinical Handbook of Biofeedback: A Step-
by-Step for Training and Practice with Mindfulness (pp. 318-319) by I.Z. Khazan, 2013, 









Appendix F – Resonance Frequency Breathing Rate Determination Template 
Resonance Frequency Breathing Rate Determination Template 





Max-min HRV Heart Rate (Rate 
smoothness and 
regularity of HR 
on scale of 1-5) 
RSA (Estimate 
synchronicity of 
heart rate and 
breath on scale of 
1-5) 
7.0 bpm   
 
  
6.5 bpm     
6.0 bpm    
 
 
5.5 bpm     
5.0 bpm     
4.5 bpm     
Note. Resonance frequency breathing rate determination template. Adapted from The Clinical 
Handbook of Biofeedback: A Step-by-Step for Training and Practice with Mindfulness (pp. 318-











Appendix G – Session-by-Session Outline 
PARTICIPANT CODE – AW85 
 
 Goals Activities Measures 
Screening Phone Call 
 
Date: 04/30/14 
Time: 6:30 pm 
(a) Determine 
participant eligibility 
(a) Review items on 
the Migraine 
Symptom Tool to 
determine eligibility 
(b) Mail and/or email 
(2) Migraine Logs 
and Descriptive 
Migraine Logs for 
baseline data 




handed out to 
establish baseline 





Time: 10:00 am 
(a) Review informed 
consent and session 
procedures 
(b) Schedule all 
biofeedback sessions 
(a) Review and sign 
informed consent 
(b) Review baseline 
Migraine Logs and 
Descriptive Migraine 
Logs 
(a) No measures 
handed out during 
post-screening 
meeting 
Session 1 (30 min) 
 
Date: 06/08/14 




(b) Obtain baseline of 
bpm 
(c) Prepare participant 
for paced breathing 





awareness of how 
breathing feels 
(a) Determine 
baseline of bpm 
(b) Obtain baseline of 
heart rate, HRV, skin 
conductance, and 
finger temperature 
(c) MSQ 2.1 
administered 
Session 2 (30 min) 
 
Date: 06/21/14 
Time: 12:00 pm 
(a) Teach paced 
breathing 
(b) Decrease 
frequency of bpm (1-2 
points) 
(c) Encourage 
breathing at 7 bpm 
(a) Practice timed, 
paced breathing 
(b) Practice breathing 
1-2 bpm lower than 
baseline 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 
Session 3 (30 min) 
 
Date: 07/05/14 
Time: 10:00 am 
(a) Determine RFB 
pattern 
(a) Practice timed, 
paced breathing at 7 
bpm and decrease 
frequency (.5 point) 
every 3 minutes 
(b) Administrator 
observes breathing 
pattern and records 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 








Sessions 4 (30 min) 
 
Date: 07/19/14 
Time: 10:00 am 
 
*Reported feeling 
dehydrated and had 
a mild headache due 
to use of alcohol the 
previous night (2 
drinks) 
(a) Train breathing at 
resonance frequency 
(b) Breathe within .5 
breaths of resonance 
frequency without use 
of pacer or visual 
feedback 
(c) Observe an 
increase in HRV and 
decrease in migraine 
symptoms compared 
to baseline measures 
(a) Practice RFB with 
visual feedback 
(b) Practice RFB 
without visual 
feedback and pacer 
depending on level of 
coherence 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 
(c) Administer MSQ 
2.1 during Session 5 
and Session 10 
Sessions 5 (30 min) 
 
Date: 07/27/14 
Time: 11:00 am 
 













rate reading was 
inconsistent and 
unstable (range of 85 
– 244bpm) 
(a) Train breathing at 
resonance frequency 
(b) Breathe within .5 
breaths of resonance 
frequency without use 
of pacer or visual 
feedback 
(c) Observe an 
increase in HRV and 
decrease in migraine 
symptoms compared 
to baseline measures 
(a) Practice RFB with 
visual feedback 
(b) Practice RFB 
without visual 
feedback and pacer 
depending on level of 
coherence 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 
(c) Administer MSQ 
2.1 during Session 5 
and Session 10 
Sessions 6 (30 min) 
 
Date: 08/02/14 
Time: 10:00 am 
(a) Train breathing at 
resonance frequency 
(b) Breathe within .5 
breaths of resonance 
frequency without use 
of pacer or visual 
feedback 
(c) Observe an 
(a) Practice RFB with 
visual feedback 
(b) Practice RFB 
without visual 
feedback and pacer 
depending on level of 
coherence 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 
(c) Administer MSQ 




increase in HRV and 
decrease in migraine 
symptoms compared 
to baseline measures 
2.1 during Session 5 
and Session 10 
Sessions 7 (30 min) 
 
Date: 08/09/14 
Time: 10:00 am 
(a) Train breathing at 
resonance frequency 
(b) Breathe within .5 
breaths of resonance 
frequency without use 
of pacer or visual 
feedback 
(c) Observe an 
increase in HRV and 
decrease in migraine 
symptoms compared 
to baseline measures 
(a) Practice RFB with 
visual feedback 
(b) Practice RFB 
without visual 
feedback and pacer 
depending on level of 
coherence 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 
(c) Administer MSQ 
2.1 during Session 5 
and Session 10 
Sessions 8 (30 min) 
 
Date: 08/16/14 
Time: 10:00 am 
(a) Train breathing at 
resonance frequency 
(b) Breathe within .5 
breaths of resonance 
frequency without use 
of pacer or visual 
feedback 
(c) Observe an 
increase in HRV and 
decrease in migraine 
symptoms compared 
to baseline measures 
(a) Practice RFB with 
visual feedback 
(b) Practice RFB 
without visual 
feedback and pacer 
depending on level of 
coherence 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 
(c) Administer MSQ 
2.1 during Session 5 
and Session 10 
Sessions 9 (30 min) 
 
Date: 08/30/14 
Time: 10:00 am 
(a) Train breathing at 
resonance frequency 
(b) Breathe within .5 
breaths of resonance 
frequency without use 
of pacer or visual 
feedback 
(c) Observe an 
increase in HRV and 
decrease in migraine 
symptoms compared 
to baseline measures 
(a) Practice RFB with 
visual feedback 
(b) Practice RFB 
without visual 
feedback and pacer 
depending on level of 
coherence 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 
(c) Administer MSQ 
2.1 during Session 5 
and Session 10 
Sessions 10 (30 min) 
 
Date: 09/06/2014 
Time: 10:00 am 
(a) Train breathing at 
resonance frequency 
(b) Breathe within .5 
breaths of resonance 
frequency without use 
of pacer or visual 
(a) Practice RFB with 
visual feedback 
during baseline 
(b) Practice RFB 
without visual 
feedback and pacer 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 





(c) Observe an 
increase in HRV and 
decrease in migraine 
symptoms compared 
to baseline measures 
depending on level of 
coherence 
finger temperature* 
(c) Administer MSQ 
2.1 during Session 5 
and Session 10 
Sessions 11 (30 min) 
 
Date: 09/20/2014 
Time: 2:00 pm 
 
*Make up session for 
lost data from 
Session 5* 
(a) Train breathing at 
resonance frequency 
(b) Breathe within .5 
breaths of resonance 
frequency without use 
of pacer or visual 
feedback 
(c) Observe an 
increase in HRV and 
decrease in migraine 
symptoms compared 
to baseline measures 
(a) Practice RFB with 
visual feedback 
during baseline 
(b) Practice RFB 
without visual 
feedback and pacer 
depending on level of 
coherence 
(a) Review Migraine 
Log and Descriptive 
Migraine Log 
(b) Observe changes 
in heart rate, HRV, 
skin conductance, and 
finger temperature* 
(c)  




Time: 12:30pm – 
Phone and email 
(a) Assess changes in 
migraine frequency 
and effects on quality-
of-life 
(a) Discuss thoughts 
and feelings regarding 
at-home-breathing 
practices and filling 
out logs 
(a) Review Migraine 
Logs and Descriptive 
Migraine Logs 





Time: 2:30pm – 
Phone call and email 
(a) Assess changes in 
migraine frequency 
and effects on quality-
of-life 
(a) Discuss thoughts 
and feelings regarding 
at-home-breathing 
practices and filling 
out logs 
(a) Review Migraine 
Logs and Descriptive 
Migraine Logs 





Time: 3:00pm – 
Phone call and email 
(a) Assess changes in 
migraine frequency 
and effects on quality-
of-life 
(a) Discuss thoughts 
and feelings regarding 
at-home-breathing 
practices and filling 
out logs 
(a) Review Migraine 
Logs and Descriptive 
Migraine Logs 
(b) Administer MSQ 
2.1 
Note. * HRV biofeedback training seeks to observe a gradual decrease in heart rate, increase in 
HRV, decrease in skin conductance, and increase in finger temperature. The intersubjective 
nature of these physiological measurements makes it difficult to define a specific set of 
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